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Abstract

Polymeric nanoparticles from amphiphilic copolymers are deemed as flexible
platforms for effective delivery of chemotherapeutic drugs to tumor tissues. The use of
cholesterol as the hydrophilic segment can confer stability upon dilution and high drug
loading capacity to these type of nanoparticles due to the tendency of cholesteryl
groups to aggregate and form liquid crystal phases. On the other hand, the
incorporation of polyethylene glycol as the hydrophilic block provides colloidal stability
and reduced opsonization. Building on previous research in the laboratory, the overall
goal of the present dissertation was to further advance the development and
understanding of novel and rationally designed cholesterol-based polymeric
nanoparticles as delivery systems to improve the therapeutic index of highly toxic
anticancer drugs.
Two types of cholesterol-based nanoparticles encapsulating the anticancer drug
doxorubicin were developed and comprehensively evaluated in this study. The first type,
formed by an amphiphilic brush-like block copolymer, displayed significant tumor growth
inhibitory activity in a mouse model and an improved safety profile compared to the free
form of the drug. However, slow drug release seemed to prevent this formulation from
displaying better efficacy results.

Laura Gonzalez-Fajardo, University of Connecticut, 2019

As a solution to the drug release pitfall, a second type of nanoparticle was
developed, incorporating a cleavable (redox-sensitive) disulfide bond in the polymer
structure to facilitate bioresponsive drug release inside cancer cells overexpressing the
reducing scavenger molecule glutathione. Evidence of the significant influence of the
method of preparation on the characteristics and performance of these doxorubicinloaded redox-sensitive polymeric nanoparticles was observed, underlying the relevance
of implementing systematic approaches like quality by design (QbD) to the development
of nanomedicines. On the other hand, proof of the cleavable nature of these secondgeneration nanoparticles and superior in vitro performance compared to the noncleavable platform was obtained, as well as evidence of their in vivo efficacy and
improved safety profile when evaluated against free doxorubicin (DOX-HCl) and the
commercial pegylated liposomal form (Doxil®)
These findings support future translational efforts regarding the developed redoxsensitive cholesterol-based polymeric nanoparticles as carriers to improve the
therapeutic index of toxic chemotherapeutic drugs, particularly in the context of
personalized medicine.
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Chapter 1.
Introduction, Aims and Organization of the Thesis

1

1.1 Introduction
Cancer is a group of diseases characterized by abnormal cells that divide
uncontrollably, invading nearby tissues and spreading to other parts of the body. It is the
third most common cause of death worldwide and it accounts for 22% of all deaths in
the US [1]. The most widespread form of cancer treatment is chemotherapy, the use of
cytotoxic compounds to kill cancer cells. However, despite the undeniable benefits of
chemotherapeutic drugs, their clinical use is often limited by toxicity; the non-specific
nature of their mechanism of action can lead to damage of normal cells specially those
rapidly dividing.
Nanocarriers harbor the potential to deliver highly toxic anticancer drugs to
tumors while limiting the exposure of healthy organs where severe or even lifethreatening adverse effects can occur. This research field, known as cancer
nanomedicine, has made significant contributions to the cancer treatment toolbox in the
past three decades, with five FDA approved products and four more currently in use in
Europe and Asia [2]. Most of these approved products are liposomal-based, due in part
to the advantages associated with liposomes like biocompatibility and stability.
However, as the field evolves several challenges to effective translation have been
identified and more chemically versatile platforms, other than liposomes, are required to
address them. Among the diverse landscape of nanocarriers, polymeric nanoparticles
from amphiphilic block copolymers are deemed as flexible and tunable delivery
platforms that efficiently incorporate hydrophobic drugs and can be tailored to display
long term plasma circulation, effective extravasation across the leaky tumor vasculature
and tissue-specific drug release [3, 4].
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In order to provide biocompatible, stable and versatile delivery platforms to
address the toxicity issues associated with conventional chemotherapy and overcome
the pitfalls of other carriers , we previously reported the synthesis and characterization
of an amphiphilic block copolymer composed of cholesterol, as the hydrophobic
segment, and polyethylene glycol, as the hydrophilic block (P(NBCh9-b-NBPEG))
(Figure 1.1). A brush-type architecture was incorporated into this polymer to confer
stability and high drug loading to the formed nanoparticles. In this case, several
segments of cholesterol and several segments of PEG were attached to a common
polynorbornene backbone. This polymer self-assembled into stable nanostructures that
encapsulated the anticancer drug doxorubicin (DOX-NPs), with high drug loading (˷
20%) [5]. DOX-NPs displayed in vitro sustained drug release kinetics, effective
internalization by human cancer cells and concentration-dependent cytotoxic activity.
Additionally, stability upon injection and long plasma circulation were observed. Initial
biodistribution studies showed that DOX-NPs accumulated in tumor tissue and reduced
the exposure of vital organs to doxorubicin when compared with the non-encapsulated
doxorubicin hydrochloride form (DOX-HCl).
On the other hand, slow and incomplete drug release in tumor tissues is a
common concern for polymeric nanoparticles. To provide tissue-specific drug release, a
cholesterol-based block copolymer with a reducible disulfide bond (PC5MA-SS-PEO)
was also designed and synthesized (Figure 1.2) [6]. It is expected that high tumor
glutathione (GSH) concentrations (10 mM -20 mM) lead to the reduction of the disulfide
bond in the polymer structure followed by nanoparticle disruption and subsequent drug
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release while low drug release in plasma is guaranteed by naturally low extracellular
GHS concentrations (10 µM).

Figure 1.1. Cholesterol-based brush-like block copolymer (P(NBCh9-b-NBPEG)).

Figure 1.2. Redox-sensitive cholesterol-based block copolymer (PC5MA-SS-PEO). The
disulfide bond in the polymer structure is highlighted in green.
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1.2 Objectives and aims
The overall goal of the present dissertation is to further advance the development
and understanding of these novel and rationally designed cholesterol-based polymeric
nanoparticles as delivery systems to improve the therapeutic index of highly toxic
anticancer drugs.
Specific aims
The specific aims of the project were:
Specific aim 1. To evaluate the efficacy and toxicity of DOX-NPs in a mouse
xenograft human tumor model and compare its effects with the non-encapsulated
form of the drug (DOX-HCl).
Specific aim 2. To prepare doxorubicin-loaded redox-sensitive polymeric
nanoparticles (DOX-SS-NPs) with optimal characteristics for in vivo administration.
Specific aim 3. To assess the redox-triggered in vitro drug release, cytotoxicity,
intracellular distribution and storage stability of DOX-SS-NPs and select the most
promising formulation to advance in the development process.
Specific aim 4. To evaluate the biodistribution, efficacy and toxicity of DOX-SS-NPs
in a mouse xenograft human tumor model and compare its effects with DOX-HCl
and the commercial pegylated liposomal form (Doxil®).

1.3 Chapter organization and outline
Chapter 2 reviews the thermodynamic and kinetic principles behind the
formation of polymeric nanoparticles from amphiphilic block copolymers as well as the
most common methods of preparation. The advantages of the use of this type of
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colloidal aggregates as delivery platforms for chemotherapeutic drugs are also
highlighted. Subsequently, the concept of bioresponsive materials to facilitate drug
release from polymeric nanoparticles is introduced along with a literature review about
redox-sensitive nanomedicines. Finally, a description of the available doxorubicin
commercial products is provided, emphasizing the need for better formulations.
Giving previous encouraging results regarding the favorable biodistribution of
doxorubicin (DOX) when administered in cholesterol-based polymeric nanoparticles
(DOX-NPs), chapter 3 assesses if the observed higher drug concentrations in tumors
tissues and lower concentrations in healthy organs, when comparing to DOX-HCl, could
translate into increased in vivo efficacy and reduced toxicity. In this chapter, a mouse
xenograft human tumor model is used to evaluate the effect of DOX-NPs on tumor
growth, survival and multi-organ toxicity.
Chapter 4 studies the impact of the method of preparation on the characteristics
of DOX-loaded redox-sensitive nanoparticles (DOX-SS-NPs). According to literature
reports, the method of preparation can have a significant effect on the properties of
drug-loaded polymeric nanoparticles from amphiphilic copolymers since the assembly of
these systems is a kinetically controlled process. In order to obtain nanoparticles with
optimal particle size distribution, shape and drug loading we compare two common
methods of preparation: 1) Cosolvent removal method and 2) O/W emulsion method.
The effect of formulation parameters is also investigated using a design of experiments
(DOE) approach. Finally, candidate formulations are selected for subsequent in vitro
evaluation.
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Chapter 5 is a comprehensive in vitro testing of two selected redox-sensitive
formulations and highlights the extension of the impact of the method of preparation
beyond the characteristics of the nanoparticles to the in vitro performance of the
formulations. This chapter studies the redox-triggered nature of drug release from the
carriers as well as the effect of DOX-SS-NPs on the viability of human cancer cells. To
further confirm drug release in biologically relevant conditions, the intracellular
distribution of the drug when administering DOX-SS-NPs is also assessed. Lastly,
chapter 5 evaluates the long term stability of the formulations at 4°C. DOX-HCl and
Doxil® are tested in most experiments described above for comparison. DOX-NPs, the
non-cleavable nanoparticles evaluated in chapter 3, are included in the cytotoxicity and
intracellular distribution studies to establish the potential advantages of a cleavable
(redox-sensitive) carrier vs a non-cleavable one.
The biodistribution of the redox-sensitive nanoparticles is evaluated in chapter 6
to confirm tumor accumulation and as a criteria to select the final formulation for in vivo
efficacy studies. Once the best formulation is identified, a dose tolerability study is
conducted in healthy mice to determine the dose of DOX-SS-NPs that allowed for
repeated administrations without life-threatening side effects, the optimal doses of DOXHCl and Doxil® are also established in this chapter. Finally, the effect of DOX-SS-NPs
on tumor growth, survival and multi-organ toxicity is evaluated in a mouse xenograft
human tumor model and compared to the effect of DOX-HCl and Doxil®.
Chapter 7 summarizes the findings of each chapter and presents the overall
conclusions of the thesis. A perspective on future steps and challenges is also provided
in this chapter.
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Chapter 2.
Polymeric Nanoparticles from Amphiphilic Block Copolymers and their
Application as Drug Deliver Platforms in Cancer Treatment

9

2.1. Abstract
Nanomedicines harbor the potential to improve the therapeutic index of toxic
anticancer drugs. Among the numerous types of nanocarriers, polymeric nanoparticles
from amphiphilic block copolymers stand out due to the possibility of carefully selecting
the hydrophobic and hydrophilic segments to confer colloidal stability, high drug loading
and long plasma circulation. Besides, thanks to the diversity in synthetic polymer
chemistry, bioresponsive segments can be introduced to promote drug release in tumor
tissues. This chapter discusses the role of nanomedicines in cancer treatment as well
as the advantages of using nanomedicines based on amphiphilic block copolymers.
Finally, details about the development and clinical performance of Doxil®, the first
approved nanomedicine, are introduced to highlight its advantages and unmet
expectations.

2.2. Nanomaterials and their applications in medicine
Materials in the nanoscale dimensions, 1-100 nm, display unique characteristics
such as large surface area to mass ratio and prevalent quantum effects that make them
very attractive for applications in electronics, catalysis and insulation among others [1].
Interest regarding the use of nanomaterials in medicine rises from the fact that
biological processes inside the human body occur at nanoscale dimensions, opening
the possibility of developing very tunable and precise diagnostic and therapeutic tools.
The early 1960s idea of nanomedicine envisioned tiny machines performing surgery at
the cellular and even molecular level [2]. As the field evolved over the years, drug
delivery, imaging contrast agents and biomarker detection became its most promising
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areas in terms of successful clinical translation [3]. It is important to highlight that from
the FDA point of view, products that involve the application of nanotechnology can also
be those that contain materials with similar dimension-dependent properties even if they
are outside the typical nanoscale range, up to 1000 nm [4].
Delivering therapeutic agents using nanomaterials, combinations known as
nanomedicines, mainly intends to alter the drug pharmacokinetics and biodistribution to
ultimately modify their efficacy and/or toxicity [5]. A group of diseases where this
approach has proven particularly attractive is cancer, mainly because of the severe
toxicity of conventional chemotherapy and the overall low treatment response in certain
malignancies.

2.3. Nanomedicines in cancer treatment
The introduction of chemotherapy in the 1940’s was a major breakthrough for
cancer treatment: remissions were possible for the very first time and the life
expectancy of patients significantly increased [6]. However, despite its undeniable
benefits, chemotherapy damage to healthy organs can lead to severe, even lifethreatening side effects. High prevalence of cancer and the limitations of conventional
chemotherapy create the need for selective treatments that can effectively kill cancer
cells with minimal effects on normal cells.
Nanocarrier mediated drug delivery is an increasingly widespread strategy to
improve the efficacy and decrease the toxicity of chemotherapeutic drugs [7]. Since the
approval of the first anticancer nanomedicine by the FDA in 1995, five other products
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have been introduced to the market while both preclinical and clinical research have
intensified [8].
As previously stated, nanomedicines are designed to alter the biodistribution and
pharmacokinetic profile of small molecules and enable their selective delivery to the
diseased tissue. Despite recent controversy [9-11], the enhanced permeability and
retention (EPR) effect is still considered the most important principle for the delivery of
macromolecules and nanomedicines to solid tumors. Large amounts of oxygen and
nutrients are required to sustain rapid cell division. In order to meet those metabolic
requirements, cancer cells overexpress proteins that promote the formation of new
blood vessels like the vascular endothelial growth factor (VEGF). This accelerated
angiogenic process leads to irregular tumor vasculature characterized by tortuous
architecture and high permeability. Widened cell junctions and increased numbers of
fenestrations allow macromolecules and nanomedicines to extravasate from the
bloodstream to tumor tissues, a process that is strictly regulated in normal tissues. On
the other hand, there are no functional lymphatic vessels inside solid tumors and those
in the tumor margin often display retrograde flow [12]. As a result, macromolecules and
nanomedicines are retained in tumors, a phenomenon known as the EPR effect or
passive targeting [13]. Due to their size, the transport of nanomedicines across
continuous endothelium is minimal, which makes their accumulation in healthy organs
much lower than the accumulation of small molecules that in contrast can easily diffuse
across continues vasculature. By taking advantage of the selective accumulation of
nanocarriers in tumor tissues, these platforms can deliver drugs to solid tumors and
reduced the exposure of off-target organs to highly toxic anticancer drugs.
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There are several requirements for the development of successful antineoplastic
nanomedicines. To effectively accumulate in tumors, nanomedicines should display
stability upon intravenous administration, long term blood circulation, and adequate
particle size and shape to cross the gaps in the tumor vasculature [14]. Additionally, to
further ensure nanomedicine safety and efficacy, the nanocarrier should be
biocompatible, ideally display high drug loading and controlled drug release kinetics.
Finally, from the manufacturing perspective nanomedicines should be easy to fabricate
and sterilize. Liposomes, solid lipid nanoparticles and inorganic nanoparticles are some
of the several nanocarriers described in the literature [15]. Aggregates in the nanoscale
range made from synthetic or natural polymers have also been used for the formulation
of nanomedicines. Thanks to the diversity in synthetic polymer chemistry, these
aggregates are flexible deliver platforms that can be tailored to display the
characteristics required for effective tumor accumulation and optimal drug release in
tumor tissues.

2.3.1. Effect of nanoparticle properties on nanomedicine performance
The successful application of nanoparticle drug delivery in cancer treatment
partially depends on key characteristics of the formulated nanocarriers. Particle size
affects the biodistribution, clearance and tumor accumulation of long-circulating
nanocarriers. Particles below 5-6 nm display short plasma circulation due to rapid renal
filtration [16] while particles above 200 nm are quickly cleared from circulation through
the spleen [17]. Longer plasma circulation usually translate into higher tumor
accumulation through the EPR effect, being particles between 50 nm - 100 nm the ones
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displaying the best accumulation in highly vascularized and permeable tumors [18]. On
the other hand, accumulation in poorly permeable tumors seems to be better for
particles between 30 and 50 nm as previously discussed by Cabral et al [19].
The shape of a nanoparticle can also affect its transport in the circulation and its
interaction with cell membranes. One of the main steps determining the transport of
flowing nanoparticles to tumors is their margination towards the walls of tumor blood
vessels. Nanoparticles have to interact with the tumor vascular bed to move from the
lumen of the vessels to the neoplastic tissues. Because nanoparticles are mainly
transported by convection in the tumor microcirculation, spherical nanoparticles are less
likely to drift towards the vessel walls than oblated-shape nanoparticles. Elliptical
nanoparticles experience torques resulting in tumbling and rotation, which increase
margination and facilitates tumor accumulation [20]. On the other hand, spherical
nanoparticles are more easily internalized by macrophages and cancer cells than
geometries with high aspect ratio which subsequently affects their biodistribution and
therapeutic efficacy [20]. Although it is clear that shape is an important attribute of
nanoparticles, there are not conclusions regarding the best geometry and
comprehensive studies correlating shape, biodistribution and efficacy are needed.
Drug loading, defined as the amount of drug in the formulation as a percentage
of total weight, is another important characteristic of nanomedicines. From the
manufacturing perspective, higher drug loading is preferable because less excipients
are used to encapsulate the same quantity of active pharmaceutical ingredient (API).
Increasing drug loading decreases the number of nanoparticles that need to be
manufactured to deliver an equivalent dose of API which in turns reduces manufacturing
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cost and processing time. Injecting a lower amount of carrier is also desirable from the
safety point of view. Additionally, maximizing drug loading may increase the chances of
high drug concentrations in tumor tissues.

2.4. Nanoparticles from amphiphilic block copolymers
A unique type of polymeric aggregates are those formed by amphiphilic block
copolymers. Amphiphilic block copolymers contain more than one type of monomer,
commonly one hydrophilic and one hydrophobic so that the resulting macromolecule
displays regions of opposite behavior in their interaction with aqueous media. The
location of these segments is sequential, meaning a clearly hydrophilic region is
followed by a hydrophobic one in opposition to random copolymers in which the
probability of a given segment at any given location is independent of the nature of the
adjacent segment. Once these amphiphilic copolymers reach certain concentration in
water, their hydrophobic segments come together and remove themselves from the
aqueous solvent giving rise to colloidal aggregates, this is a spontaneous process
driven by an increase in the entropy of the surrounding water molecules also known as
the hydrophobic effect. Depending on the molecular weight of the polymer, the size of
the hydrophobic and hydrophilic segments and the interfacial tension between the
hydrophobic segment and water these aggregates can arrange into polymeric micelles,
polymeric nanoparticles or polymersomes. The structures above are typical of
copolymers with two consecutive blocks since polymers with three or more alternate
blocks can form other type of aggregates.
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Polymeric micelles display a spherical, core/shell structure where the core is
formed by the hydrophobic segments of the polymer chains and the shell is formed by
the hydrophilic fragments. In analogy to small molecular weight lipid surfactants,
polymeric micelles are dynamic association colloids since the polymer chains in the
aggregates are at equilibrium with the polymer chains in the continuous phase.
Therefore, they are not considered solid particles. In order to form polymeric micelles
the interfacial tension between the hydrophobic segment and water must be low enough
to allow polymer chains to leave the micelle, exposing its lipophilic region to the
aqueous solvent. Other factors such as steric hindrance between the chains in the core
and in the shell may also play a role on determining if there is a relevant dynamic
exchange of polymer chains between the aggregates and the solvent [21]. Polymeric
micelles displayed a mobile fluid-like core in which hydrophobic drugs can be
solubilized.
On the other hand, polymeric nanoparticles from amphiphilic block copolymers,
also known as nanospheres, display the same core/shell structure of polymeric micelles
but their core is solid-like in nature. In this case, dynamic equilibrium is absent and the
aggregates are rather kinetically frozen due to the high energy penalty of a polymer
chain leaving the aggregate [21, 22]. When the interfacial tension between the
segments in the core and the aqueous media is high, block-copolymers will form
polymeric nanoparticles instead of micelles. Nanospheres can be seen as solid
polymeric matrixes in which hydrophobic drugs are dissolved, entrapped, encapsulated
or adsorbed.
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A third type of aggregates from amphiphilic block copolymers are polymersomes.
Polymersomes are spherical vesicles formed by a water inner phase surrounded by a
polymeric bilayer. In the bilayer, the hydrophilic segments of the polymer face the
internal and external water phases while the hydrophobic segments constitute the inner
part of the membrane. Polymersomes are usually formed by polymers in which the
hydrophilic segment accounts for 10-40% of the total polymer mass and the interfacial
tension between the hydrophobic segment and the aqueous media is high [23]. As
analogous to liposomes, polymersomes find utility in the encapsulation of water soluble
drugs which can be entrapped in the aqueous inner compartment.
The flexibility provided by amphiphilic block copolymers in terms of the diverse
nanostructures that can be obtain is one of the reasons why there is wide spread
interest in their use for drug delivery. In the present work, we focus on the development
of polymeric nanoparticles from amphiphilic block copolymers for the delivery of potent
anticancer drugs to tumor tissues since there are many advantages related to their use
in cancer nanomedicine. First of all, the hydrophilic shell in polymeric nanoparticles
provides compatibility with the aqueous environment and reduces the internalization by
cells of the reticuloendothelial system (RES) while strong interactions between the
segments in the hydrophobic core lead to low critical aggregation concentration (CAC)
values (10-6 – 10-8 M) and subsequent stability upon dilution in the blood stream.
Furthermore, the hydrophobic core permits the effective incorporation of drugs with low
water solubility. On the other hand, their size range (10 nm- 200 nm) allows them to
cross the tumor vasculature while preventing renal filtration [24, 25].
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The stability of this type of polymeric nanoparticles in storage and upon
administration is largely affected by the interactions among the segments in the
hydrophobic core. Because of the strong tendency for self-association of cholesteryl
groups, as well as their structural rigidity and biocompatibility self-assembled polymeric
nanoparticles with cholesterol core have been investigated for drug delivery applications
in the past [26-28].

2.4.1. Cholesterol as the hydrophobic segment of amphiphilic block copolymers
Cholesterol is a lipid molecule of the sterol class with a paramount biological
role. As a major component of animal cell membranes, cholesterol regulates membrane
fluidity and permeability; cell membranes with high cholesterol content, such as the
ones in the epidermis, have high stability and low permeability. It also serves as a
precursor for steroid hormones, bile acids and vitamin D. The ring structure of
cholesterol make it a planar and rigid molecule (Figure 2.1). Due to its alkyl chain,
cholesterol is mostly hydrophobic but the hydroxyl group in one of the cyclohexane rings
confers it a weakly amphiphilic character. This hydroxyl group also facilitates chemical
modifications and conjugations such as the formation of cholesteryl esters when
reacting with acetyl halides.
Both small molecules and macromolecules bearing cholesteryl groups can
self-assemble into liquid crystal mesophases, a phenomenon first described in 1888 by
the Austrian scientist Friedrich Reinitzerwhile while working on the physicochemical
properties of cholesteryl benzoate. Liquid crystal mesophases display extensive order in
the molecular scale that can extend to form domains in the micrometer range but does
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not reach macroscopic dimensions as observed in crystals. Using cholesteryl groups as
the hydrophobic building blocks in amphiphilic block copolymers is an interesting
approach given their ability to self-assemble through hydrophobic interactions and form
liquid crystal mesophases, promoting the self-assembly of the polymer chains and
providing great stability to the aggregates. In that way, a water soluble polymer like
polyethylene glycol (PEG) can be modified into an associative polymer by the addition
of cholesteryl segments. The strong tendency for self-association of cholesterol and its
rigidity provides very stable hydrophobic cores once the polymer assembles into
aggregates [26, 29]. These cholesterol-based aggregates display low CAC values (10-6
–10-8 M), which favors stability upon dilution in blood circulation, and high drug loading
(5-15%) [27, 30, 31]. Being a component of cell membranes and precursor of hormones
and vitamins, cholesterol is a biocompatible material, which make it ideal for
applications in drug delivery.

Figure 2.1. Chemical structure of cholesterol. Source:
http://www.chemspider.com/Chemical-Structure.5775.html?rid=d3896c06-105e-4a43bd08-fdc14398f6e0
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2.4.2. PEG as the hydrophilic segment of amphiphilic copolymers
One of the biggest challenges for nanomedicines in cancer treatment is their
quick removal from blood circulation by the reticuloendothelial system (RES) via
recognition of opsonins adsorbed on the particle surface by receptors on the cell
membranes of phagocytes [32, 33]. Longer circulation time is desirable since it
increases the probability of the nanomedicine reaching tumor tissues. Coating the
surface of nanoparticles with hydrophilic polymers, like dextrans or polyglycerols but
most commonly polyethylene glycol (PEGylation) is a widely spread strategy to reduce
internalization by the RES [34]. Polyethylene glycol (PEG) is a polymer of ethylene
oxide (Figure 2.2) also known as polyethylene oxide (PEO) or polyoxyethylene (POE).
PEGs of different molecular weights (200 g/mol to 500,000, g/mol) are commercially
available for numerous applications in the food, cosmetic and pharmaceutic industries
as surfactants, dispersant agents and cosolvents. Due to its hydrophilic nature, PEG
chains produce a bulky hydration cloud that sterically prevents NPs from interacting with
blood components like opsonins. Furthermore, the conformational freedom provided by
the flexibility of PEG makes the interpenetration of proteins into the PEG corona
thermodynamically unfavorable [35]. On the other hand, the positive interaction between
PEG and water molecules confers stability to the nanoparticles in aqueous media while
the bulky nature of hydrated PEG prevents particle size increase over time due to
nanoparticle aggregation, also known as steric stabilization. Furthermore, PEG has low
intrinsic toxicity which make it ideal for biological applications [36].
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n
Figure 2.2. Polyethylene glycol structure. Modified from
http://www.chemspider.com/Chemical-Structure.13835235.html?rid=018ece52-03d447cc-aca5-c8d5341d2a9d

2.4.3. Brush-like amphiphilic block copolymers
An important category of amphiphilic block copolymers are those with a brushtype architecture, also known as graft polymers. These polymers are formed by a
backbone densely grafted with hydrophilic and hydrophobic segments as side chains,
arranged in a block order (Figure 2.3) [37]. These large domain structures, can confer
better colloidal stability and biodistribution due to a strong shielding effect provided by
numerous hydrophobic segments while drug loading can be also high since there are
many hydrophobic fragments available to interact with hydrophobic drugs.

Figure 2.3. Architecture of brush copolymers. Taken from Yu Y et al [37].
21

2.4.4. Methods of preparation of polymeric nanoparticles from amphiphilic block
copolymers
Because polymeric nanoparticles are kinetically trapped systems, their
characteristics are determined by the method of preparation. Several methods have
been reported in the literature, being nanoprecipitation and dialysis the most commonly
used due to their simplicity and the fact that a large energy input such as sonication is
not required.

2.4.4.1. Cosolvent removal
Also known as nanoprecipitation or solvent displacement method. It relies on a
rapid decrease in the quality of the solvent by the addition of water. Initially, both the
drug and the polymer are dissolved in a water miscible organic solvent (e.g. ethanol,
acetone or dimethylformamide). This solution is then added to a stirred aqueous phase
which can only solubilize the hydrophilic segment of the copolymer, triggering the selfassembly of the hydrophobic segments. Subsequently, the organic solvent is eliminated
by evaporation or dialysis [38]. Some drug molecules are entrapped during the
nanoparticle formation process while free molecules can be removed by dialysis or
ultrafiltration. Parameters like polymer concentration, stirring speed, and the ratio
organic solvent to water can affect particle size distribution and drug loading. An
advantage of this technique is that the use of a homogenizer or a sonicator is not
required, facilitating scale-up and manufacturing. Moreover, many water miscible
organic solvents are class 3 (i.e. regarded as less toxic by the FDA) and higher residual
amounts are acceptable [39], contributing to a simpler manufacturing process. On the
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other hand, the selection of an adequate organic solvent can be difficult since it needs
to dissolve both the polymer and the drug [40].

2.4.4.2. O/W emulsion
In this method, the drug is dissolved in a volatile and non-water miscible organic
solvent (e.g. dichloromethane or chloroform) to create an emulsion when adding the
organic phase to water. The polymer can be either dissolve in the organic solvent or
suspended in the aqueous phase as blank nanoparticles. The formation of the emulsion
is facilitated by a high energy source (e.g. sonicator or homogenizer). This step is
critical to the nanoparticle formation. Subsequently, the organic solvent is evaporated by
stirring the emulsions at room temperature and pressure or under reduced pressure
[41]. During the formation of the emulsion the amphiphilic polymers will most likely be
located at the interface between the organic solvent and water. As the solvent
evaporates, the polymer chains assembly and drug molecules are entrapped in the
polymer matrix. Parameters like type of organic solvent, polymer concentration, energy
source and rate of evaporation can all affect the final nanoparticle characteristics. A
disadvantage of this method is the use of class 2 solvents (e.g. chloroform and
dichloromethane) which are known to display inherent toxicity so the allowed residual
amounts are in the order of 60 – 600 ppm. The use of class 2 solvents require further
efforts to assure that the final content is below the residual limits stablished by the FDA.
In some cases, chloroform and dichloromethane can be replace by ethyl acetate, a
class 3 solvent.
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2.4.4.3. Dialysis
In this method, the polymer and the drug are dissolved in a water miscible
organic solvent and the solution is dialyzed against water. The slow replacement of the
organic solvent with water (i.e. a bad solvent for the hydrophobic block) promotes the
self-assembly of the polymer chains. During this process some drug molecules are
entrapped in the core of the nanoparticles while free molecules can be removed during
dialysis. This method is very popular in laboratory settings, however, it is not suitable for
large scale production and it tends to produced polydispersed aggregates due to the
slow change in the quality of the solvent [41].

2.5. Redox-sensitive nanomedicines
Rapid and complete drug release from nanoparticles at the diseased tissues
remains challenging, potentially compromising the therapeutic effects of nanomedicines.
To overcome this drawback, several successful attempts to develop bio-responsive
nanocarriers have been reported [42]. With this approach, the main goal is to develop
delivery platforms that can rapidly and selectively release their cargo once exposed to
specific stimuli within the tumor microenvironment or inside cancer cells to improve the
efficacy of the nano-therapeutics and the safety profiles via site-specific release of their
carried drugs.
Redox-sensitive nanocarriers are of particular interest because of higher GSH
levels in tumor tissues compared to normal tissues (10—20 mM vs. 0.5—10 mM) [43,
44] and plasma (1-10 µM) [45], thus enabling the inherent biochemistry of tumors to be
utilized for therapeutic benefit. A diverse array of nanocarriers including polymeric
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micelles [46] [47], liposomes [48], and silica nanoparticles [49] have been designed to
quickly respond to the intracellular reducing environment to facilitate drug release,
increase cytotoxicity, and subsequently improve the efficacy of chemotherapeutic drugs
delivered by nanocarriers. There is much evidence suggesting that the presence of
redox sensitive moieties, most commonly disulfide bonds, provides nanoparticles with
faster drug release and subsequently improved in vitro cytotoxicity.
Kim et al. incorporated cystamine as a redox-sensitive cross-linker in the core of
poly(ethylene oxide)-b-poly(methacrylic acid) polymeric micelles to facilitate drug
release at high intracellular GSH concentrations [50]. In vitro release of the anticancer
drug doxorubicin (DOX) from this formulation was effectively promoted by GSH and
cysteine in a concentration-dependent manner. Interestingly, the IC50 of DOX
encapsulated in redox-sensitive micelles in A2780 ovarian carcinoma cells was 0.12
µM, while the IC50 of DOX encapsulated in non-redox-sensitive micelles was 0.7 µM,
confirming the hypothesis that higher cytotoxic activity can be achieved through redoxtriggered drug release.
A targeted delivery system for the hydrophobic drug paclitaxel (PTX) was
developed by Li et al. based on redox-sensitive hyaluronic acid-deoxycholic acid (HAss-DOCA) conjugates [51]. Hyaluronic acid (HA) was included as a targeting ligand
since cancer cells often over-express HA receptors (CD44) on their surface [52]. These
conjugates aggregate in aqueous media, encapsulating PTX in the hydrophobic core.
Rapid drug release from HA-ss-DOCA micelles was observed under reducing
conditions (90% release after 24 h, 20 mM DTT), while little release was detected from
non-redox-sensitive micelles (HA-DOCA) in the same release media (10% release after
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24 h). PTX encapsulated in HA-ss-DOCA micelles was more than twice as potent as
PTX encapsulated in HA-DOCA micelles when measuring in vitro cytotoxicity in MDAMB-231 breast cancer cells treated for 72 hours (IC50 0.03 µM vs. 0.07 µM).
Redox-sensitive nanocarriers containing anticancer drugs not only outperform
the anticancer activity of their non-sensitive counterparts in vitro, but also in vivo. In
order to provide structural stability and controlled release through cross-linking, Li et al.
designed reversible, disulfide cross-linked polymeric micelles composed of PEG,
dendritic oligolysine, and cholic acid [46]. Cysteine was incorporated into the
telodendrimers to provide a disulfide cross-link (PEG5k-Cys4-L8-CA8), and the thiolfree telodendrimer, PEG5k-CA8, was also synthesized for comparison. PTX was
incorporated into the micelles followed by cross-linking of the cysteine residues by
oxidation. PTX release from PTX-DCM (cross-linked, redox-sensitive micelles) was
facilitated as the levels of GSH in the media increased. In the absence of GSH, release
from PTX-DCM was slower than release from PTX-NCM (non-cross-linked, non-redoxsensitive micelles). Notably, the tumor growth rate of mice treated with 5 doses of 10
mg PTX/kg PTX-DCM was significantly lower compared to those treated with the same
dose of PTX-NCM (percent tumor growth inhibition with respect to the PBS control was
67% vs. 42%, estimated from the relative tumor volume figure), and both formulations
were superior to FDA-approved Taxol®.
In a similar cross-linking approach, Koo et al. obtained redox-sensitive micelles
via self-assembly of poly(ethylene glycol)-b-poly(Lysine)-b-poly(L-phenylalanine) (PEGPLys-PPhe) followed by cross-linking with 3,3'-dithiobis(sulfosuccinimidylpropionate)
(DTSSP), a disulfide-containing compound [47]. Docetaxel (DTX) release from cross-
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linked micelles increased when GSH was present in the media in a concentrationdependent manner. The cross-linked, redox-sensitive micelles displayed longer in vivo
circulation and higher tumor accumulation than their non-cross-linked counterparts.
Reduction in tumor growth rate was greater in the group treated with the cross-linked
redox-sensitive formulation than with the non-cross-linked formulation (percent tumor
growth inhibition with respect to the saline control was 83% vs. 70%, calculated
estimated from the tumor volume figure). This enhanced in vivo efficacy likely resulted
from the combination of minimized drug loss in circulation, enhanced accumulation in
tumor tissues, and rapid intracellular drug release [47].
Overall, it has been demonstrated by several groups that drugs encapsulated in
redox-sensitive delivery platforms display greater in vitro cytotoxicity and in vivo efficacy
than their non-redox-sensitive counterparts. However, in most cases, it is unknown
where in the cell and how the reduction occurs as well as the factors affecting the
reaction kinetics.
The successful clinical translation of redox-sensitive nanomedicines is a complex
process that involves overcoming multiple challenges [53] such as 1) limited knowledge
of the off-target effects in organs with high GHS expression, 2) lack of methods of
preparation that can be scale up to industrial dimensions and 3) unknown variation in
the GHS expression in human tumors. To address these knowledge gaps, first, it is
necessary to conduct extensive preclinical research to demonstrate efficacy and safety.
So far, most in vivo studies have emphasized efficacy evaluation but comprehensive
safety assessment is lacking. In that sense, organs with high GSH levels and high
tendencies for nanoparticle accumulation, such as the liver, deserve special attention.
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Additionally, the use of well-known and traditionally used materials may facilitate the
achievement of suitable safety profiles and reduced costs of preclinical evaluation, as
information regarding their in vivo degradation profiles is already available. On the other
hand, the scale-up phase may be hastened thorough the understanding of process and
formulation parameters and their effects on the characteristics and performance of the
nanomedicines early in the research process. The early selection of preparation
methods that can be used in a manufacturing setting is also a sound approach. Once
the preclinical phase is completed, the next challenge is the selection of the clinical
indication and the design of the clinical study. Selection of patients for clinical studies
based on nanoparticle deposition in tumors as suggested by Lee et al. may increase the
probabilities of observing positive clinical outcomes [54]. In the particular case of redoxsensitive nanoparticles, selection of patients can be further complemented by
determining the tumor redox status through the use of redox-sensitive imaging probes
[55].

2.6. Doxorubicin and Doxil®
Doxorubicin, also known as adriamicyn, is a potent drug from the anthracycline
family first discovered in 1969 by Italian researchers [56] and extensively used in the
treatment of several malignancies including breast, lung, gastric, ovarian and thyroid
cancer, as well as non-Hodgkin’s and Hodgkin’s lymphoma, sarcoma, and leukemia
(Figure 2.4).
The main mechanism of action of doxorubicin is DNA damage (i.e. single and
double strand breaks) mediated by the enzyme topoisomerase II. In the presence of

28

ATP, topoisomerase II catalyzes a number of topological isomerization reactions by
binding to the DNA strands and causing transient DNA breaks. This intermediate breaks
allow the DNA to be untangled for replication and transcription and at the end of these
processes the DNA backbone is resealed from topoisomerase II and the strands are
linked back together. Doxorubicin affects the breakage-reunion reaction by stabilizing
the complex formed by topoisomerase II and DNA, interfering with DNA replication and
RNA synthesis [57].
The non-specific nature of its mechanism of action causes doxorubicin to be very
toxic not only for cancer cells but also for healthy cells, especially those of rapid
duplication. Therefore, doxorubicin treatment is associated with several side effects,
being cardiotoxicity the most serious. Doxorubicin cardiotoxicity manifests as
progressive myocardial damage that may lead to congestive heart failure. The risk of
developing cardiotoxicity increased with the accumulative dose, an estimate 5%
patients develop congestive heart failure at a cumulative dose of 400 mg/m2, rising to
16% at a dose of 500 mg/m2, 26% at a dose of 550 mg/m2, and 48% at a dose of 700
mg/m2. Cardiotoxicity limits the utility of doxorubicin in the clinic since lower doses have
to be administered or doxorubicin has to be replace for alternative and potentially less
effective agents [58]. Myelosuppression is another dose limiting side effect of
doxorubicin. This bone marrow effects may result in increased incidence of
infections, hindered healing and gingival bleeding. Other common side effects of
doxorubicin are acute nausea and vomiting, stomatitis, gastrointestinal disturbances,
liver toxicity and alopecia [59]. The broad clinical use of doxorubicin and its dose limiting
side effects made this drug a good candidate for the development of nanomedicines.
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Figure 2.4. Chemical structure of doxorubicin. Source:
http://www.chemspider.com/Chemical-Structure.29400.html?rid=d406dc3a-9fdd-4346abc0-e055ca2b9a8c

After extensive research and optimization, in 1995 the FDA approved the first
nanomedicine known as Doxil®. Doxil® is a liposomal formulation of doxorubicin
designed to evade RES internalization by the incorporation of PEGylated 1,2-distearoylsn-glycero-3-phosphoethanolamine (PEG2000-DSPE). Doxil® was initially approved for
the treatment of Kaposi’s sarcoma, a common malignancy in patients living with
HIV/AIDS and subsequently its indications expanded to recurrent ovarian cancer,
metastatic breast cancer and multiple myeloma.
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In humans, Doxil® is much better tolerated than conventional doxorubicin, being
its major benefits a reduction in the incidence of serious side effects, including cardiac
toxicity, and an improvement in patience quality of life. Nonetheless, Doxil® displays
unique side effects such as mucositis and severe desquamating dermatitis (“foot and
hand syndrome”) that limit the doses that can be administered to patients. As a
consequence, Doxil® does not displayed better efficacy when compared to the standard
of care treatment [60, 61]. Next-generation doxorubicin nanomedicines could met the
increased efficacy expectation by addressing the issues associated with Doxil® toxicity,
including skin accumulation and uncontrolled drug release in the skin so higher doses
can be administered. On the other hand, manufacturing issues have cause shortage of
Doxil® in recent years [62], therefore, nanomedicines that can be fabricated by simple
and reproducible methods are desirable.
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Chapter 3.
Reduced In Vivo Toxicity of Doxorubicin by Encapsulation in CholesterolContaining Self-Assembled Nanoparticles
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3.1. Abstract
Our laboratory previously reported the development of an amphiphilic brush-like
block copolymer composed of polynorbornene-cholesterol/polyethylene glycol
(P(NBCh9-b-NBPEG)) that self-assembles in aqueous media to form long circulating
nanostructures capable of encapsulating doxorubicin (DOX-NPs). Biodistribution studies
showed that this formulation preferentially accumulates in tumor tissue with markedly
reduced accumulation in the heart and other major organs. The aim of this chapter was
to evaluate the in vivo efficacy and toxicity of DOX-NPs in a mouse xenograft human
tumor model and compare its effects with the hydrochloride non-encapsulated form of
the drug (DOX-HCl). DOX-NPs significantly reduced the growth of tumors without
inducing any apparent toxicity. Conversely, mice treated with DOX-HCl exhibited
significant weight loss, early toxic cardiomyopathy, acute toxic hepatopathy, reduced
hematopoiesis and fatal toxicity. The improved safety profile of the polymeric DOX-NPs
can be explained by the low circulating concentration of non-nanoparticle-associated
drug as well as the reduced accumulation of DOX in off-target organs.

3.2 . Introduction
Despite its many indications in clinical oncology, the use of doxorubicin (DOX) is
limited by potentially fatal and irreversible cardiotoxicity [1, 2]. Liposomal formulations
on the market (e, g., Doxil® and Myocet®) have partially addressed this issue [3-5].
However, different side effects from what is observed with the hydrochloride free form of
DOX such as hand-foot syndrome, and complement activation-related pseudo-allergy
may require dose reduction or treatment discontinuation depending on the severity of
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the symptoms [6-8]. Liposome-encapsulated DOX can also exert toxic effects on the
liver macrophage population with impaired phagocytic function and reduced ability of
colloid particle clearance [9]. Furthermore, the complexity of its manufacturing process,
especially in the case of Doxil®, increases the risk of critical drug shortage [10].
Polymeric self-assembled nanoparticles from amphiphilic block copolymers offer
several advantages over other nanocarriers for drug delivery such as tunable particle
size, high loading capacity of hydrophobic drugs, flexible chemistry, and colloidal
stability [11]. Recently, polymeric nanoparticles from brush amphiphilic copolymers are
gaining attention as delivery systems because of their low critical aggregation
concentrations (CAC) and subsequent high stability upon dilution [12]. Brush type
architecture with biocompatible side chain units can be envisioned to obtain amphiphilic
brush block copolymers capable of forming stable biocompatible nanoparticles which
can encapsulate hydrophobic DOX. Delivery of DOX using polymeric self-assembled
nanoparticles has been extensively investigated in the past, providing evidence of
improved biodistribution and reduced tumor growth [13-15]. However, reports about the
safety of the drug-carrier systems and their organ specific effects are scarce since most
of the reports either do not include in vivo toxicity studies or evaluate reduction in body
weight as the only sign of toxicity.
Our laboratory previously reported the development of self-assembled
nanoparticles formed from a cholesterol-based brush copolymer capable of
encapsulating hydrophobic DOX. Besides displaying excellent stability, prolonged in
vivo circulation and high tumor accumulation, this nanoparticle formulation (DOX-NPs)
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significantly reduced DOX accumulation in the heart, liver and spleen of tumor-bearing
mice [16].
To further advance the development process and fully evaluate this drug delivery
system we studied drug release in biorelevant media, assessed the biocompatibility of
the nanocarrier and evaluated the efficacy and toxicity of this nanoparticle formulation in
a mouse xenograft tumor model in comparison with the hydrochloride non-encapsulated
form of the drug (DOX-HCl).

3.3. Methods and materials

3.3.1. Materials
Doxorubicin hydrochloride (DOX-HCl) was purchased from Biotang Inc.
(Waltham, MA, USA). Triethylamine (TEA) and dimethylformamide (DMF) were
purchased from Fisher Scientific (Boston, MA, USA). Penicillin−streptomycin, 0.25%
(w/v) trypsin 0.03% (w/v)-EDTA solution, RPMI 1640, and DMEM were purchased from
American Type Culture Collection (Rockville, MD, USA). The human lung cancer cell
line (A549) was purchased from the American Type Culture Collection (Manassas, VA,
USA). Fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Norcross, GA,
USA). Human plasma and plasma from BALB/c mice were purchased from Innovative
Research (Novi, MI, USA). Spectra/Pro dialysis membranes were obtained from
Spectrum Laboratories (Rancho Dominguez, CA, USA). Centrifugal filters were
purchased from Millipore (Darmstadt, Germany). Esterase from porcine liver (3.2 M
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(NH4)2SO4, 28.1 mg of protein/ml, 218 units/mg of protein) was obtained from SigmaAldrich (St Louis, MO, USA). All chemicals were analytical or HPLC grade.

3.3.2. Synthesis and Purification of P(NBCh9-b-NBPEG)
Synthesis of norbornene functionalized monomers, 5-{9(cholesteryloxycarbonyl)-nonyloxycarbonyl}-bicyclo[2.2.1]hept-2-ene (NBCh9) and
methoxy polyethylene glycol (MPEG) (Mn = 2 Kg/mol) functionalized norbornene
(NBPEG) was previously reported [17] [18]. All brush-like block copolymers were
synthesized using ring opening metathesis polymerization (ROMP), the synthesis and
characterization details are described in a previous publication [18]

3.3.3. Preparation and characterization of blank nanoparticles and DOX-NPs.
The preparation and characterization of blank and DOX-containing nanoparticles
was described in a previous publication [16]. Briefly, blank nanoparticles were prepared
by dissolving the polymer in DMF and subsequent dialysis of the solution against
ultrapure water for 48 hours. For the preparation of DOX-NPs, hydrophobic DOX was
obtained by deprotonation of DOX-HCl solubilized in DMF with TEA. The reaction was
allowed to proceed overnight at room temperature. Later on, deprotonated DOX was
added to the polymer solution in DMF, at a mass ratio of 1:3 (drug: polymer), and the
mixture was stirred for 1 hour at room temperature. Finally, the solution was dialyzed for
48-72 hours to allow the polymeric nanoparticles to form. The nanoparticles were
purified by centrifugation at 8000 rpm for 10 min, followed by filtration through 0.45 μm
filter. To eliminate non-nanoparticle-associated soluble DOX, the nanoparticles were

40

ultrafiltered (MWCO 10 kDa) with centrifugation at 8000 rpm for 10 minutes.
Nanoparticle suspensions were kept at 4°C until use or lyophilized and stored at 4°C.
The average particle size and size distribution were measured using a nanoparticle
tracking analysis instrument (Nanosight, Malvern, UK). The amount of DOX-loaded into
nanoparticles was determined by interpolation in a standard curve of concentration vs
absorbance at 480 nm using an UV−Vis spectrophotometer (Shimadzu, Japan).

3.3.4. In vitro release of DOX from nanoparticles in biorelevant media
To rule out the possibility of burst and esterase-mediated release of DOX in
plasma, DOX-NPs were incubated with media containing various levels of esterase
activity. PBS buffer (pH 7.4), 10% human plasma, 10% mouse plasma, 10% A549
cancer cells homogenate and carboxylesterase equivalent to 10% mouse plasma (1.86
units/ml) were evaluated for their ability to release DOX from the nanoparticles,
presumably due to cleavage of ester bonds in the polymer structure. Nanoparticles
equivalent to 20 µg/ml DOX were incubated with the release media at 37°C with
agitation at 100 rpm for 24 hours. In all cases, the release media contained 0.1% (w/v)
Tween-80. Ultrafiltration using a 10 kDa filter and centrifugation at 8000 rpm and 37°C
for 1 hour was used to separate DOX released from the nanoparticles. DOX in the
filtrate was quantified by fluorescence spectroscopy at 480/560 excitation/emission.
In vitro drug release over time was studied by incubating nanoparticles
equivalent to 10 µg/ml of DOX with PBS (pH 7.4) or PBS containing carboxylesterase.
At each time point (4, 24, 48, 72 and 144 hours), 1 ml aliquots were removed for
quantification of DOX released from the nanoparticles and 1 ml of fresh media was
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added to keep a constant volume of 20 ml. In all cases, release media contained 0.1%
(w/v) Tween-80. Ultrafiltration using a 10 kDa filter and centrifugation at 8000 rpm and
37°C for 1 hour was used to separate released DOX from the nanoparticles. DOX in the
filtrate was quantified by fluorescence spectroscopy at 480/560 excitation/emission.

3.3.5 Quantification of non-nanoparticle-associated DOX and DOX-NPs in plasma
of mice treated with DOX-NPs
SCID mice at 6-8 weeks of age received a single dose of DOX-NPs or DOX-HCl
equivalent to 5 mg/kg of DOX via tail vein injection. At 0.25 and 2 hours post injection,
blood was collected by cardiac puncture. Plasma was separated by centrifugation (3000
rpm, 10 min, and 4°C). In plasma from mice injected with DOX-NPs, ultrafiltration using
a 50 kDa filter and centrifugation at 8000 rpm and 5°C for 1 hour was used to separate
non-nanoparticle-associated DOX from the nanoparticles. Non-nanoparticle-associated
DOX was directly quantified by fluorescence as described above. DOX-NPs and free
DOX-HCl were quantified by fluorescence after extraction from plasma with acidic
isopropanol as described in Shi et al [19].

3.3.6. Evaluation of the effect of blank NPs on tumor bearing SCID mice
All animal studies were performed according to an approved protocol by
Institutional Animal Care and Use Committee (IACUC) at the University of Connecticut.
To evaluate in vivo effects of i.v administration of blank nanoparticles without drug, 10
SCID mice at 6-8 weeks of age were inoculated subcutaneously with 2x106 A549 cells.
Two weeks after tumor implantation, mice were randomly divided into two groups (n=5).
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One group received 6 mg/kg blank nanoparticles twice per week, while the control
group received saline. Tumor size and body weight, as an indicator of systemic toxicity,
were monitored three times per week. Tumor volume was calculated using the following
equation: tumor volume (mm3) = width2 x length/2. Treatment was administered for 6
weeks, followed by plasma and major organs collection for pathology and biochemical
analysis. Organs were fixed in 10% buffered formalin and embedded in paraffin. Four
micron sections were sliced and stained using Hematoxylin & Eosin staining (H&E).
Histological changes in heart, liver and spleen were determined by pathology analysis.

3.3.7. Anti-tumor efficacy and toxicity of DOX-NPs and free DOX-HCl
The antitumor activity of DOX-HCl and DOX-NPs was evaluated in tumor-bearing
SCID mice inoculated subcutaneously in the right flank with 2 × 106 A549 cells. When
the tumors grew to an average size of 30 mm3, mice were randomly divided into four
treatment groups containing four mice each (n=4): 5 mg/kg DOX-NPs, 5 mg/kg DOXHCl, 1 mg/kg DOX-HCl and saline. Mice treated with 5 mg/kg DOX-NPs and saline were
injected intravenously once a week via the tail vein. Due to high toxicity at the site of
injection that prevents frequent administration of DOX-HCl via tail vein injection, mice
receiving 5 and 1 mg/kg DOX-HCl were injected intraperitoneally once a week. Previous
studies have reported similar plasma and liver concentrations of DOX after i.v and i.p
administration in nude mice even though concentrations in other organs like heart and
muscle may be affected by the route of administration [20]. Tumor size and body weight
were monitored three times per week. After 8 weeks of treatment, mice were sacrificed
and plasma and major organs were collected for pathology and biochemical analysis.
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3.3.8. Alanine aminotransferase (ALT) assay
ALT plasma levels were determined as a biomarker for liver damage in mice after
8 weeks of treatment with 5 mg/kg DOX-NPs, 1 mg/kg DOX-HCl or saline once per
week. Infinity ALT Liquid Stable Reagent (Thermo Fisher Scientific Inc., Waltham, MA)
was used to determine ALT activity. Briefly, 100 μl of reagent was added to 10 μl serum
or plasma samples, and absorbance was measured spectrophotometrically at 340 nm
using a Bio-Tek Power Wave X Spectrophotometer. ALT activity (U/l) was determined
using the molar extinction coefficient of NADH (6.3 mM−1cm−1).

3.3.9. Cardiac troponin assay
The mouse cardiac troponin-I ultra-sensitive ELISA kit (Life Diagnostics, PA,
USA) was used to quantify cardiac troponin levels in plasma samples from mice treated
with 5 mg/kg DOX-NPs, 1 mg/kg DOX-HCl or saline once per week for 8 weeks. Mouse
plasma was separated from blood collected through submandibular bleeding.

3.3.10. Statistical analysis
One-way ANOVA or the Kruskal-Wallis tests were used to establish statistical
differences among groups. Tukey's or Dunn´s Multiple Comparison tests were
performed to compare each treatment group with the other groups, according to the
parametric or non-parametric distribution of data. Survival curves were generated using
the Gelhan Wilcoxon method. Analyses were performed with GraphPad Prism 6
software (GraphPad Inc., San Diego, CA), and P values < 0.05 were considered
significant.
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3.4. Results and discussion

3.4.1. Nanoparticle characterization
The characterization parameters for the polymer, blank nanoparticles and DOXNPs are summarized in Table 3.1.

Table 3.1. Characterization of blank and DOX-loaded nanoparticles from P(NBCh9-bNBMPEG)
a

Block
copolymer

Mn
(Kg/mol)

Wt. Fraction (%)
b
(NMR)

c

Feed
ratio

Particle
size (nm)

DLC
(%)

d

e

EE
(%)

GPC (PDI)

NBCh9

NBMPEG

162 (1.3)

7.45

92.54

-

83.7 ± 1.1

-

-

162 (1.3)

7.45

92.54

1:3

94.5 ± 2.0

14.5

58.0

(PNBCh9)-b(PNBMPEG)
(PNBCh9)-b(PNBMPEG)
a

Molecular weight was determined by GPC relative to PMMA standards with dimethyl
acetamide (DMAc) as eluent.
b
Weight percent of monomer was determined by 1H NMR integration of peaks at 4.6 for
cholesterol and 3.35 for PEG side chains.
c
DOX:polymer feed weight ratio
d
DLC, drug loading content.
e
EE, encapsulation efficiency.

3.4.2. In vitro release of DOX from nanoparticles in biorelevant media
An initial concern about the in vivo performance of DOX-NPs in the mouse model
was the possibility of uncontrolled drug release trigged by esterases. Preceding works
have reported rapid release of drugs from nanoparticles prepared with ester containing

45

compounds in mouse plasma due to its high esterase activity [21-23]. Both PEG and
cholesterol are bound to the polynorbornene backbone through ester bonds. Therefore
media with reported esterase activity were included in the study to rule out the
possibility of uncontrolled release triggered by esterases as highlighted by previous
publications [21, 22]. It is known that mouse plasma and cancer cells exhibit relatively
high esterase activity compared to human plasma and PBS (22). After 24 hours of
incubation, an overall increase in the release of DOX was observed in the presence of
different media when compared with PBS alone (cumulative release = 6%). Human
plasma produced a mild increase (11.2%) while carboxylesterases (14.5%), A549 cell
lysate (20%) and mouse plasma (20.6%) exhibited a more pronounced effect (Figure
3.1A). To further investigate the effect of esterases on the release of DOX from the
nanoparticles, the in vitro release in the presence of carboxylesterases was studied
over time. At each time point, drug release was higher in the media containing
carboxylesterases than in media without enzymes (Figure 3.1B), reaching a maximum
release of 16% after 48 hours while the highest release observed for PBS was 10.8%
after 144 hours. The limited extent of the release in the presence of esterases suggests
that burst release in circulation due to enzymatic activity is not a concern for this DOXNPs.
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Figure 3.1. Release of DOX from DOX-NPs at 37°C. A) Media with different levels of
esterase activity. One way ANOVA test, *p < 0.05, ***p < 0.001 ****p < 0.0001. B) Media
with carboxylesterases. Data are based on 3 independent experiments and are
expressed as means ± SD.

3.4.3. Non-nanoparticle-associated DOX in circulation
To estimate the amount of drug in the non-nanoparticle-associated form after the
administration of DOX-NPs to mice, we separated the nanoparticles by ultrafiltration and
quantified the non-nanoparticle-associated drug in the filtrate. At two time points after
injection, 0.25 and 2 hours, the encapsulated form made the majority of the total drug in
circulation, 92% and 88.4% respectively (Figure 3.2). The concentrations of nonnanoparticle-associated DOX after the administration of DOX-NPs, at 0.25 and 2 hours
were 1.9 µg/ml and 2.1 µg/ml respectively. As previously reported [16], the
concentration of DOX-HCl rapidly decreased from 25 µg/ml at 0.25 hours to 5 µg/ml at 2
hours. The concentration of non-nanoparticle-associated DOX in plasma was 13.2 and
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2.4 times lower than the concentration of free drug when administering DOX-HCl at 0.25
h and 2 h time points respectively (Figure 3.2). These results suggest that release of
DOX in circulation is minimal, which ensures that little drug reaches tissues with healthy
continue vasculature.

Figure 3.2. DOX concentrations in plasma expressed in the form of DOX-NPs and Nonnanoparticle-associated DOX after the administration of 5 mg/kg DOX-NPs, as well as
DOX-HCl after the administration of 5 mg/kg DOX-HCl (n = 3; mean ± SD). One way
ANOVA test, **** p < 0.0001.

3.4.4. Evaluation of the effect of blank NPs on tumor bearing SCID mice
To evaluate the biocompatibility of P(NBCh9-b-NBPEG) nanoparticles, we
studied the effects of blank nanoparticles on tumor bearing SCID mice by treating them
with a dose of 6 mg/kg polymer mass, twice a week for 6 weeks. There were no
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significant differences in the body weight or tumor growth of mice treated with blank
nanoparticles when compared to the control group (Figure 3.3). No lesions were found
in the hearts, livers or spleens of mice treated with blank nanoparticles (Figure 3.4). No
significant increase in ALT plasma levels were detected in mice treated with blank
nanoparticles compared to mice treated with saline (24.1 ± 0.2 U/l vs 23.4 ± 6.1 U/l,
respectively), being the average base line value for healthy mice 15.3 ± 2.0 U/l.
Potential effects in the liver where a particular concern since nanoparticles in general
tend to accumulate in this organ. However, results showed that the administration of
blank nanoparticle did not induced changes in the liver function of mice.

Figure 3.3. Effect of the administration of 6 mg/kg blank NPs, twice per week on tumorbearing SCID mice. A) Body weight. B) Tumor growth ratio (Volume/Initial Volume), (n =
5; mean ± SD).
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There are very few reports of polynorbornenes intended for biomedical
applications and none of those studies evaluated their effects in vivo [24-26]. This study
constitutes the first report of the in vivo safety evaluation of a polymer containing a
polynorbornene backbone and the results strongly suggest that it is a biocompatible
material.

Figure 3.4. Histology of tissues from tumor bearing SCID mice treated with 6 mg/kg
blank NPs, twice a week for 6 weeks.
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3.4.5. Anti-tumor efficacy and toxicity of DOX-NPs and DOX-HCl
DOX-NPs significantly reduced the growth of tumors after 40 days of treatment.
Tumor growth was also inhibited by 1 mg/kg DOX-HCl but the inhibition reached
statistical significance only at day 54 (Figure 3.5). The effect of 5 mg/kg DOX-HCl could
not be assessed because mice in this group died after the second dose, presumably
from high systemic toxicity.

Figure 3.5. Effect of the administration of 5 mg/kg DOX-NPs, once per week, on tumor
growth. Comparison of the tumor inhibition effect of DOX-NPs versus DOX-HCl and
saline. Data are shown as tumor growth ratio relative to the initial tumor size (V/Vo), (n =
4; mean ± SD).*Statistical significant difference between DOX-NPs and saline, one way
ANOVA test, p < 0.05. ** Statistical significant difference between DOX-NPs and saline
p < 0.01.#Statistical significant difference between DOX-HCl and saline, one way
ANOVA test, p < 0.05.
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One can attribute the good efficacy results of DOX-NPs to three major factors: 1)
extended systemic circulation time, 2) extravasation and tumor accumulation and 3)
interaction with the target cells [27]. The size of these DOX-NPs (94.5 nm) prevents
them from diffusing through the endothelial layer of normal blood vessels or being
excreted by renal filtration. The external PEG block of the nanoparticles reduces their
internalization by RES cells therefore prolonging their circulation in the blood, as
previously reported [16]. This likely increases their chances of interacting with tumor
tissues. The small particle size also allows them to cross the leaky tumor vasculature
and accumulate in tumor tissues by the enhanced permeability and retention (EPR)
effect. Finally, the fact that drug release increased when incubating with A549 cell lysate
and the evidence of cell internalization (16) suggest that once inside the cells, DOX can
be slowly released from the nanoparticles by enzymatic activity which also contributes
to the observed anti-tumor effect.
DOX-NPs did not induce weight loss in treated mice while 1 mg/kg DOX-HCl
induced an average weight loss of 26.1% by the end of the study. Mice treated with 5
mg/kg DOX-HCl showed a 28.1% average weight lost after receiving just two doses
(Figure 3.6A). DOX-NPs significantly increased the survival rate of tumor bearing mice
compared to DOX-HCl. All the mice treated with DOX-NPs survived the full treatment
course without showing signs of systemic toxicity (Figure 3.6B). On the other hand,
100% of the mice treated with 5 mg/kg DOX-HCl died two weeks after the treatment
started while 100% of the mice treated with 1 mg/kg DOX-HCl died by day 54. Seventy
five percent of the mice treated with saline survived the full treatment course (Figure
3.6B). The toxicity of DOX-HCl caused the low survival of the tumor-bearing mice.
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Figure 3.6. Safety of the administration of 5 mg/kg DOX-NPs on tumor-bearing mice,
once per week. Data are expressed as mean (n = 4) ± SD. A) Body weight.
****Statistically significant differences between DOX-HCl 5 mg/kg and saline, One-way
ANOVA test, p < 0.0001. #Statistically significant differences between DOX-HCl 1 mg/kg
and saline, ANOVA test, p < 0.05. B) Survival. *Statistically significant differences
between DOX-HCl 5 mg/kg and saline, Gelhan-Wilcoxon test, p < 0.05.

Regarding the effect of the treatments in organs that are common targets of DOX
toxicity, mice treated with 1 mg/kg and 5 mg/kg DOX-HCl showed signs of early toxic
cardiomyopathy characterized by cardiac muscle cell striation disruption and granularity
with some eosinophilic and vacuolated sarcoplasm and pyknotic endothelial cell nuclei
in the capillary network. Signs of acute toxic hepatopathy such as hypercellularity due to
an increased number of neutrophils as well as early signs of necrosis, including nuclear
fading (karyolysis), nuclear shrinkage (pyknosis) and fragmentation (karyorrhexys), and
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hemosiderin accumulation in Kupffer cells, were observed in the livers of mice treated
with free DOX. Reduced hematopoiesis, lymphoid germinal center absence and spleen
necrosis were observed as well (Figure 3.7). Remarkably, no significant lesions were
found in the livers, hearts, spleens or kidneys of any of the mice treated with DOX-NPs.
Tissue histology was indistinguishable from that of normal saline controls.

Figure 3.7. Effect of treatment in the tissues of tumor-bearing SCID mice. Heart) Early
signs of necrosis in cardiac tissue are highlighted with red arrows: cardiac muscle cell
striation disruption and granularity and sarcoplasmic vacuolations. Liver) Early signs of
necrosis in hepatic tissue are highlighted with red arrows: nuclear fading (karyolysis),
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nuclear shrinkage (pyknosis) and fragmentation (karyorrhexys). Spleen) Lymphoid
germinal center absence is highlighted with red arrows.

Plasma ALT levels were measured as a biomarker for liver damage. Tumorbearing mice treated with 1 mg/kg DOX-HCl showed a significant increase in ALT
values (146.8 ± 4.9 U/l) when compared to healthy mice (15.3 ± 2.0 U/l) and tumor
bearing mice treated with saline (23.4 ± 6.0 U/l). No significant alterations of ALT
plasma levels were found in the DOX-NPs treated group (19.5 ± 4.4 U/l) after 8 weeks
of treatment (Figure 3.8A). Cardiac troponin I quantification suggests that the levels of
this heart damage marker increased in mice treated with DOX-HCl 1 mg/kg once a
week for 8 weeks and also with single dose administration of 20 mg/kg DOX-HCl
(Figure 3.8B). No alterations were found in mice treated with DOX-NPS in comparison
to saline control group.
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Figure 3.8 Plasma ALT and troponin levels from mice treated with saline, DOX-HCl or
DOX-NPs. A) ALT is expressed as international units (U) per liter (n = 4; mean ± SD).
The average detected ALT level of healthy controls was 15.3 U/l. ***Statistically
significant differences between DOX-HCl and the other treatment groups, one way
ANOVA test, p < 0.0005. B) Plasma troponin (n = 3; mean ± SD). The average
detected troponin level of the healthy controls was 0.081 ng/ml. One way ANOVA test,
*p < 0.05, **p < 0.01.

Overall, compared to DOX-HCl, DOX-NPs exhibited a remarkable improvement
in the safety profile. A close link exists between DOX accumulation in the heart, and the
development of cardiomyopathy [28]. Bone marrow exposure to DOX also determines
the severity of myelosuppression [29]. These striking differences can be largely explain
by a) the notable change in the biodistribution of DOX, when administered as DOX-NPs,
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reported in our previous study in which DOX accumulation in heart, liver and spleen was
reduced 3.9, 6.5 and 4.6 times respectively [16] and b) the fact that most of the drug in
circulation stays in the encapsulated form. When administering the same dose of DOXHCl and DOX-NPs, the released DOX from DOX-NPs in blood was small compared to
the amount of drug available to diffuse to the non-target organs after administration of
DOX and cause toxic effects. Finally, even when some of the nanoparticles can
accumulate in the reticulo-endothelial system, the slow release of the drug from the
nanoparticles has a protective effect since only the non-nanoparticle-associated form
can exert toxic effects when binding to cellular targets.
Previous reports have pointed out the potential of polymer nanoparticles to limit
DOX cardiac toxicity and myelosuppression [30-32]. We carefully evaluated the drug
release profiles of our DOX-NPs both in vitro and in vivo, and assessed their tissue
toxicity and anti-tumor efficacy. The results demonstrated the potential of the system to
be a safer and more effective therapeutic agent to treat cancer. In addition, our DOXNPs provide the advantage of a simple preparation process that yields a relatively high
drug loading (14-20%), making them advantageous based not only on their therapeutic
effect, but also from the manufacturing perspective.

3.5. Conclusion
Self-assembled nanoparticles formed from cholesterol-based brush-like block
copolymers proved to be safe for repeated administration. Treatment of tumor-bearing
mice with DOX-NPs significantly reduced tumor growth without inducing DOX-HCl
associated cardiac, liver toxicity or myelosuppression, providing 100% survival by the

57

end of the study. The improved safety profile of DOX-NPs can be explained by low
release of DOX from the nanoparticles in plasma and subsequent low circulating
concentration of non-nanoparticle-associated drug as well as the reduced accumulation
of DOX in major organs like heart, liver and spleen. These findings support the use of
P(NBCh9-b-NBPEG) nanoparticles as a delivery platform for hydrophobic anticancer
drugs intended to reduce the toxicity of conventional treatments.
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Chapter 4.
Optimization of a Cholesterol-based Polymeric Nanoparticle Formulation for
Bioresponsive Release of Doxorubicin in Tumor Cells: Impact of the Preparation
Method on Critical Nanoparticle Properties
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4.1. Abstract
Achieving selective drug release from nanoparticles in tumor tissues remains a
challenge, which compromises the therapeutic effects of nanomedicines. In order to
overcome this drawback, we designed a redox-sensitive cholesterol-based block
copolymer (PC5MA-SS-PEO) that self-assembles into nanoparticles. A reducible
disulfide bond was incorporated in the polymer structure to facilitate drug release once
the bond is cleaved by intracellular glutathione (GSH) in tumor cells. The main objective
of this chapter was to optimize the incorporation of doxorubicin (DOX) in redox-sensitive
polymeric nanoparticles formed by PCMA-SS-PEO (DOX-SS-NPs) by understanding
the effect of the method of preparation on critical nanoparticle attributes using a design
of experiment (DOE) approach. Two methods of preparation were compared; the
cosolvent removal method provided nanoparticles with small average particle size and
narrow particle size distribution but low drug loading while the O/W emulsion method
produced bigger nanoparticles with relatively high drug loading. Significant influence of
the method of preparation and formulation parameters on nanoparticle properties was
observed and the best formulations were identified for further evaluation.

4.2. Introduction
Achieving rapid and selective drug release in tumor tissues is paramount to the
development of efficacious nanomedicines. In that sense, several attempts to develop
bioresponsive nanocarriers have been reported [1]. In this approach, the main goal is to
produce delivery platforms that can quickly release their cargo once exposed to specific
stimuli in the tumor microenvironment or inside cancer cells. Redox-sensitive
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nanocarriers are of particular interest because of higher glutathione (GSH)
concentrations in tumor tissues compared to normal tissues [2, 3] and plasma, thus
enabling the inherent biochemistry of tumors to be leveraged for therapeutic benefit.
GSH is the most abundant scavenger molecule in mammalian cells; in the presence of
the enzyme glutathione peroxidase, GSH reduces toxic free radicals, preventing them
from oxidizing cellular components [4]. By increasing their GSH levels cancer cells
become resistant to oxidative stress, including the one induced by chemotherapy or
ionizing radiation [5]. When comparing redox-sensitive nanomedicines with their nonredox sensitive counterparts, an average increase in the in vivo antitumor activity
between 13 – 25% has been reported [6].
Having in mind the promising application of redox-sensitive nanomedicines, our
collaborators at the Institute of Material Sciences synthesized a cholesterol-based
copolymer (PC5MA-SS-PEO) with a disulfide bond in the structure to facilitate drug
release in the reducing environment inside tumor cells (Figure 4.1). Once in aqueous
media, PC5MA-SS-PEO self-assembles into nanoparticles in which drugs like
doxorubicin can be incorporated.

Figure 4.1. PC5MA-SS-PEO chemical structure. a)
Cholesteryl segment.

On the other hand, the successful
application of nanoparticle drug delivery in cancer
treatment depends on key characteristics of the
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formulated nanocarriers such as particle size and drug loading. Several studies
emphasize the significant effect of the preparation method on the characteristics of
nanoparticles formed by high molecular weight amphiphilic block copolymers [7, 8]. This
type of nanoparticles are kinetically frozen aggregates instead of systems in dynamic
equilibrium [9], which explains the relevance of the preparation method. In this study,
we compared two of the most common methods summarized in chapter 2: 1) the
cosolvent removal and 2) the O/W emulsion method. The first method involves the
dissolution of the polymer and the drug in a water miscible organic solvent followed by
the addition of water, which triggers polymer aggregation, and the subsequent
elimination of the organic solvent by dialysis or evaporation. The second method
requires the dissolution of the drug in a water-immiscible organic solvent followed by the
addition of the organic solvent to the aqueous phase to form an emulsion. In this case,
the polymer may be dissolved in the organic phase or may be present in the aqueous
media in the form of blank nanoparticles. Finally, the organic solvent is removed by
evaporation, leaving the drug molecules entrapped in the nanoparticles [10]. Despite its
advantages the dialysis method was not selected for evaluation because preliminary
experiments showed that very polydispersed nanoparticles (PDI > 0.3) were obtained
when using this method. Simultaneously, specific process and formulation parameters
in each preparation method can affect the final properties of the nanoparticles [10-12]. A
proper identification of significant parameters, through a DOE approach for instance, is
paramount for the development of nanoparticles with adequate characteristics for in vivo
administration.
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The main objective of this chapter was to optimize the loading of doxorubicin
(DOX) in redox-sensitive nanoparticles formed by PC5MA-SS-PEO (DOX-SS-NPs), by
testing two methods of preparation as well as different formulation parameters to finally
select the best formulations for in vitro testing.

4.3. Methods

4.3.1. Materials
Doxorubicin hydrochloride (DOX-HCl) was purchased from Biotang Inc.
(Waltham, MA, USA). Triethylamine (TEA), acetonitrile (ACN) and N,Ndimethylformamide were purchased from Fisher Scientific (Boston, MA, USA).
Dimethylsulfoxide (DMSO), chloroform (Chl), dichloromethane (DCM) and trifluoroacetic
acid (TFA) were purchase from Sigma-Aldrich (St Louis, Missouri, USA). Spectra/Pro
dialysis membranes (MWC: 12 kDa) were obtained from Spectrum Laboratories,
100Inc. (RanchoDominguez, CA, USA). Centrifugal filters were purchased from
Millipore (Darmstadt, Germany). All chemicals were either analytical or HPLC grade.

4.3.2. Synthesis and characterization of PC5MA-SS-PEO
The synthesis and characterization of PC5MA-SS-PEO was done in Dr.
Rajeswari Kasi laboratory at the Institute of Material Science, University of Connecticut.
The disulfide block copolymer comprising a polymethacrylate block bearing a
cholesterol moiety and a polyethylene glycol block was synthesized as described in a
previous publication [13]. 1HNMR was used to confirm the polymer structure and
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determine the composition of the copolymer while gel permeation chromatography
(GPC) was employed to establish its number average molecular weight (Mn) and
polydispersity (PDI).

4.3.3. Preparation of DOX-SS-NPs
Regardless of the method of preparation, DOX-HCl was initially treated with TEA
before loading to obtain the deprotonated and less water-soluble form of the drug.

4.3.3.1. Cosolvent removal method
DMF was selected as the water miscible solvent to use, because it was able to
solubilize both the polymer and the drug. Briefly, DOX-HCl was dissolved in DMF at a
concentration of 0.83 mg/ml. TEA was added to the solution and the mixture was stirred
overnight to facilitate the deprotonation of DOX-HCl. The next day, 2.5 mg of PC5MASS-PEO were dissolved in 1 ml of DMF using bath sonication for 20 minutes followed
by the addition of 1 ml of the drug solution in DMF. The polymer-drug mixture was
stirred for 1 hour at room temperature. Subsequently, the whole 2 ml of the drugpolymer solution were added to 3 ml of ultrapure water in a dropwise manner under
vigorous agitation (600 rpm). After completing the addition, the mixture was stirred for 1
hour at room temperature and then transferred to a dialysis bag (MWC 12 kDa) and
dialyzed against ultrapure water for 48 h with frequent water changes. For this method,
only the effect of the TEA:DOX molar ratio was studied. Two TEA:DOX molar ratios
were tested: 3:1 and 12:1. The evaluated responses were the average particle size (Z-
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average), polydispersity index (PDI), %drug loading (%DL) and %encapsulation
efficiency (%EE).

4.3.3.2. O/W emulsion method
This method was adapted from Kataoka et al [14]. In this case, we studied the
effect of the TEA:DOX molar ratio and the organic solvent on the properties of the
nanoparticles using a 22 full factorial design. Two TEA:DOX molar ratios (6:1 and 12:1)
and two organic solvents (Chl and DCM) were tested. The evaluated responses were
the same mentioned in the cosolvent removal method. DOX-HCl was dissolved in 50 µl
of DMSO and subsequently Chl or DCM containing TEA were added to the mixture for a
final DOX concentration of 1.24 mg/ml. The mixture was stirred overnight at 300 rpm.
700 µl of the drug solution were added to a water suspension of blank nanoparticles
(0.5 mg/ml, final volume 5 ml) in a dropwise manner under vigorous agitation (600 rpm).
The mixture was sonicated using a probe sonicator (20% amplitude) in between organic
solvent additions to facilitate the formation of the emulsion (3 sonication cycles, 1
minute/cycle). Subsequently, the organic solvent was evaporated by vigorously stirring
the emulsion overnight at 600 rpm.

4.3.3.3. Purification of DOX-SS-NPs
The following procedure was used to purify DOX-SS-NPs regardless of the initial
method of preparation. After preparation, nanoparticle suspensions were collected and
centrifuged at 8000 rpm for 10 minutes to eliminate large precipitates. Filtration through
a 0.45 µm filter was used for further purification. To eliminate soluble, non-encapsulated
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drug, ultrafiltration through a 30 kDa filter was used. The ultrafiltration was done by
centrifugation at 5000 rpm, for 20 minutes at 20ºC. This step was repeated until no drug
was detected in the filtrate using absorbance at 480 nm to detect DOX. Subsequently,
the nanoparticles were resuspended to a theoretical concentration of 1 mg/ml and
stored at 4°C until analysis.

4.3.4. Characterization of DOX-SS-NPs

4.3.4.1. Particle size distribution and morphology
Z-average and PDI of DOX-SS-NPs (0.1 mg/ml in ultrapure water) were
measured using a dynamic light scattering (DLS) instrument (Malvern Zetasizer Nano
Series, Malvern Instruments, UK). Zeta potential was measured using the same
instrument but adjusting the nanoparticle concentration to 0.5 – 1 mg/ml using 1 mM
NaCl to ensure that the conductivity of the samples range from 0.2 to 0.3 (mS/ml). The
morphology of DOX-SS-NPs was imaged by transmission electron microscopy (TEM),
(Tecnai 12 G2 Spirit BioTWIN, FEI, USA). Specimens were prepared by adding 3 µl of
the nanoparticle suspension (1 mg/ml) to a carbon film grid followed by incubation
during 2 minutes and a subsequent wash with 100 µl of a 0.5% uranyl acetate solution
in ultrapure water. Samples were air-dried before analysis.

4.3.4.2. Determination of drug loading and encapsulation efficiency
The amount of DOX-loaded into the nanoparticles was determined by highperformance liquid chromatography (HPLC). Lyophilized nanoparticles were dissolved
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in a mixture of 60% ACN and 40% DMSO to obtain clear solutions with final
nanoparticle concentrations of 0.3 mg/ml. Subsequent dilutions were made with mobile
phase (30% ACN and 70% ultrapure water containing 0.05% TFA) followed by
centrifugation at 3000 rpm for 5 min to eliminate potential precipitates before analysis.
The solutions were analyzed using an HPLC apparatus equipped with an autosampler
and a fluorescence detector (Shimadzu, Kyoto, Japan). A 10 μl sample was injected
onto a C18 column (5 μm, 250 × 4.6 mm, Agilent, Santa Clara, CA). The flow rate was 1
ml/min, and the peaks were monitored by fluorescence detection at excitation and
emission wavelength (Ex/Em) of 480/558 nm. The amount of drug in the samples was
calculated by interpolation in a standard curve of DOX-HCl.

4.3.5. Statistical Analysis
For formulations prepared by the cosolvent removal method, the Student’s t-test
was used to establish statistical differences among conditions. This analysis was
performed with GraphPad Prism 6 software (GraphPad Inc., San Diego, CA), and P
values <0.05 were considered significant. For formulations prepared by the O/W
emulsion method, a full factorial DOE analysis was conducted using Minitab 18
statistical software (Minitab Inc., State College, PA: Minitab). All experiments were
conducted in at least three independent experimental replicates.
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4.4. Results and Discussion

4.4.1. Synthesis and characterization of PC5MA-SS-PEO
Table 4.1 summarizes the molecular characterization of PC5MA-SS-PEO.

Table 4.1. Molecular characterization of the redox-sensitive polymer PC5MA-SS-PEO.
Weight fractiona %
C5MA

PEO-SS-RAFT

Molecular
weightb
(kDa)

Theoretical

15

85

24.1

-

Experimental

17

83

23.4b

1.12

PDI

a

Weight fraction of each block in the copolymer calculated using 1HNMR spectra by
comparing the ratio of the integrals of peaks at 5.33 ppm (olefin group in cholesteryl
moiety) and 3.64 ppm (PEO repeating unit).
b
Number average molecular weight (Mn) determined by GPC at 40°C with
tetrahydrofuran (THF) as the mobile phase and polystyrene as the standards.

4.4.2. Preparation of DOX-SS-NP
The method of preparation as well as the specific evaluated formulation
parameters had a significant impact on the properties of DOX-SS-NPs. The cosolvent
removal method produced small (Z-average: 60 – 80 nm) and relatively monodispersed
nanoparticles (PDI: 0.15-0.2) (Figure 4.2). In this method, the rapid decrease in the
quality of the solvent lead to the formation of small nanoparticles that quickly become
kinetically frozen, preventing further growth [15]. The TEA:DOX molar radio had a small
but significant effect on the particle size distribution; nanoparticles prepared with a
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higher ratio were slightly bigger and more monodispersed. Regarding the morphology of
the nanoparticles, at a low TEA:DOX ratio mainly spherical homogenous particles were
observed (Figure 4.3). Once the TEA:DOX ratio increased, cylindrical aggregates were
also formed. It has been proposed that PEG can form complexes with cations in
solution leading to a more compact conformation of the PEG chains [16-18]. In our
case, an interaction between PEG and positively charged TEA accompanied by a
change in the conformation of PEG may have led to alterations in the packing of the
polymer chains since a decrease in the curvature of the aggregates (e.g. from spheres
to cylinders) can result from a reduction in the size of the hydrophilic groups [19].

Figure 4.2. Particle size distribution of DOX-SS-NPs prepared by the cosolvent removal
method. The Student’s t-test was used to establish significant differences *p<0.05,
**p<0.01.

72

Figure 4.3. TEM images of DOX-SS-NPs prepared by the cosolvent removal method.
Scale bars are 100 nm.

Drug loading for particles prepared by the cosolvent removal method was low
(0.4 -2.0%) and increased with a higher TEA-DOX ratio (Figure 4.4). The deprotonated
form of the drug can partition better into the hydrophobic core of the nanoparticles,
therefore, it is expected that as the amount of TEA in the media increases, the pH
increases too and the deprotonated form becomes predominant, leading to higher drug
loading. One possible explanation for the observed low drug loading with this particular
method of preparation, can be that the assembly of the nanoparticles is slow compared
to the diffusion of the drug molecules, reducing the probability of entrapment.
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Figure 4.4. Drug loading and encapsulation efficiency of DOX-SS-NPs prepared by the
cosolvent removal method. The Student’s t-test was used to establish significant
differences among conditions, *p<0.05.

On the other hand, the O/W emulsion method produced bigger nanoparticles
than the cosolvent removal method (Z-average: 140 – 200 nm) (Figure 4.5). One
potential explanation for this observation is that the solubility of the polymer in the
organic solvent increased the mobility of the polymer chains promoting rearranging and
growth. The DOE analysis revealed that the organic solvent and more notoriously, the
interaction between the organic solvent and the TEA:DOX molar ratio significantly
affected Z-average (Figure 4.5). Overall, the use of DCM increased particle size, but
this effect was more notorious at a higher TEA:DOX molar ratio; at a low TEA:DOX
molar ratio the size of nanoparticles prepared with Chl and DCM is relatively close
(161.5 nm vs 167.7 nm) while at a high ratio, nanoparticles prepared with Chl are much
smaller than those prepare with DCM (142.7 nm vs 204.1 nm). The obtained model for
size was the following:
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Size (nm) = 161.5 + 4.5*(Solvent) - 18.8*(TEA) + 51.0 (Solvent)*(TEA); R-sq = 85.6%
Where Solvent = 0 for Chl or 1 for DCM and TEA = 0 for a TEA:DOX molar ratio of 6 or
1 if the TEA:DOX molar ratio is 12.
All the coefficients in this model were significantly different from zero except the
TEA coefficient since the effect of the TEA:DOX molar ratio on particle size was not
significant. An R-sq value of 85.6% indicates that most of the variation is due to the
evaluated parameters. However, there is a part of the variation than cannot be
explained by the model. Factors like the amount of DMSO used during the preparation
or the sonication process may contribute to this undetermined variation. The statistical
analysis also indicated that there was a significant effect of the solvent on the
polydispersity of the nanoparticles. The magnitude of this effect is minimal, being the
nanoparticles prepared with DCM slightly more polydispersed than those prepared with
Chl (Figure 4.5).
Regarding the morphology of the nanoparticles, a similar observation to that
made for the cosolvent removal method was found; increasing the amount of TEA
change the morphology of the nanoparticles from relatively homogeneous spheres to
other architectures, including cylinders and collapsed vesicles (Figure 4.6).
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Figure 4.5. Particle size distribution of DOX-SS-NPs prepared by the O/W emulsion
method.

Figure 4.6. TEM images of DOX-SS-NPs prepared by the O/W emulsion method. Scale
bars are 100 nm.

76

The drug loading of nanoparticles prepared by the O/W emulsion method (5 14%) was much higher than the one obtained in the cosolvent removal method (0.4 2%), these values are similar to those reported in other publications [20]. Previous
studies have emphasize that high drug loading can be achieved when employing this
preparation method [8, 20] due to the interaction between the organic solvent and the
nanoparticle core leading to deposition of the drug in the core once the solvent has
evaporated. On the other hand, the TEA:DOX molar ratio significantly affected drug
loading and encapsulation efficiency of nanoparticles prepared by the O/W emulsion
method. For both solvents, drug loading increased as the TEA:DOX molar ratio
increased (Figure 4.7).

Figure 4.7. Drug loading and encapsulation efficiency of DOX-SS-NPs prepared by the
O/W emulsion method.

As highlighted by Kataoka et al [14], a key factor in achieving a high drug loading
is to increase the partition of DOX from the aqueous phase to the organic phase, which
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depends on the level of protonation of DOX that decreases when the TEA:DOX molar
ratio increases making the drug more hydrophobic and therefore increasing its
concentration in the organic phase. The organic solvent also had a significant effect on
drug loading and encapsulation efficiency, being DCM the solvent leading to greater
drug entrapment. A faster evaporation rate of DCM compared to Chl may decrease the
diffusion of drug from the organic phase to the aqueous phase facilitating higher drug
entrapment. The obtained models for %drug loading and %encapsulation efficiency
were the following:
%Drug Loading = 3.9 + 4.0*(Solvent) + 5.2*(TEA); R-sq = 83.6%
%Encapsulation Efficiency = 15.2 + 15.7*(Solvent) + 21.6*(TEA); R-sq = 83.2%
Where Solvent = 0 for Chl or 1 for DCM and TEA = 0 for a TEA:DOX molar ratio of 6 or
1 if the TEA:DOX molar ratio is 12.
All the coefficients in this model were significantly different from zero. R-sq
values around 83% indicate that most of the variation is due to the evaluated
parameters. However, there is a part of the variation than cannot be explained by the
model. Factors mentioned above such as amount of DMSO and sonication may have
contributed to this undetermined variation. Interestingly, a positive and significant linear
correlation between particle size and drug loading was observed when analyzing data
from both methods of preparation (Figure 4.8).
The characterization of DOX-SS-NPs is summarized in Table 4.2. In order to
select a formulation for subsequent testing, we considered three criteria: 1) average
particle size ideally below 100 nm, 2) high drug loading to maximize the amount of drug
reaching tumor tissues and 3) homogeneous morphology of the nanoparticles. Since
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none of the formulations simultaneously meet the above criteria, we selected
Formulation 2 and Formulation 4 for further testing. Formulation 2 was selected
because its particle size distribution seemed optimal for tumor accumulation via the
EPR effect while Formulation 4 was selected because its higher drug content may allow
for higher drug concentrations in tumor tissues. Both formulations were homogeneous
in shape and therefore suitable to move forward.

Figure 4.8. Linear correlation between particle size and drug loading.
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Table 4.2. Characterization of DOX-SS-NPs prepared by different methods.
No

Method

TEA:DOX

Organic
solvent

Z-average
(nm)

%Drug
loading

%EE

1

CR

3

DMF

61.4 ± 4.4

0.21 ± 0.01 Spherical

0.5 ± 0.2

2.0 ± 0.6

2

CR

12

DMF

71.0 ± 6.6

0.16 ± 0.03 Spherical

1.9 ± 0.7

7.7 ± 3.1

3

O/W

6

Chl

161.5 ± 12.7

0.16 ± 0.04 Spherical

4.6 ± 0.6

18.5 ± 2.4

4

O/W

6

DCM

167.7 ± 3.6

0.17 ± 0.02 Spherical

7.6 ± 1.5

30.2 ± 5.9

5

O/W

12

Chl

142.7 ± 12.0

0.1 ± 0.02

Irregular

8.8 ± 0.3

35.1 ± 1.1

6

O/W

12

DCM

198.1 ± 8.4

0.16 ± 0.04

Irregular

13.7 ± 2.4

54.6 ± 9.5

PDI

Shape

4.5. Conclusions
In this formulation study, we observed a significant influence of the method of
preparation on the properties of drug-loaded nanoparticles. Consequently, for each
method of preparation, critical formulation parameters were identified. However,
variation due to factors that were not evaluated seems to account for an important
fraction of the observed differences (~15%). Future identification of those factors can
improve the reproducibility of the nanoparticle preparation process. Two formulations
were selected for further evaluation, according to in vivo administration criteria.
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Chapter 5.
In vitro Evaluation of a Cholesterol-based Polymeric Nanoparticle Formulation for
Bioresponsive Release of Doxorubicin in Tumor Cells: Impact of Nanoparticle
Properties on In vitro Performance
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5.1. Abstract
Two redox-sensitive polymeric nanoparticle formulations containing DOX
(Formulation 2 and Formulation 4) were identified as adequate for in vivo administration
based on their particle size distribution, shape and drug loading. This chapter describes
the in vitro evaluation of Formulation 2 and Formulation 4 in terms of drug release,
cytotoxic activity in cancer cells, intracellular distribution and long-term storage stability.
The redox-sensitive character of these formulations was confirmed as in vitro drug
release increased under reducing conditions while a comparison with the commercial
liposomal form of DOX (Doxil®), whose release was not affected by the reducing status
of the media, emphasizes the specificity of the drug release mechanisms in the redoxsensitive nanoparticles (DOX-SS-NPs). Significant differences between formulations
were observed regarding their in vitro performance. Interestingly, the impact of the
method of preparation extended beyond nanoparticle properties to release kinetics and
cytotoxic activity. Finally, the results from this extensive in vitro evaluation suggest that
Formulation 4 is the most promising formulation.

5.2. Introduction
Once drug-loaded nanoparticles have been prepared and characterized in terms
of particle size and drug loading, there are some additional in vitro tests that can unveil
important attributes of the formulations such us drug release, storage stability and
cytotoxic activity. Conducting these tests facilitates a comprehensive characterization of
the developed formulations and sheds light onto their potential in vivo performance.
Having two promising doxorubicin-loaded redox-sensitive nanoparticle formulations, it
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was important to conduct further in vitro testing to confirm their redox-sensitive
properties and make an informed selection for subsequent in vivo studies.
Despite several nanoparticle-based products on the market and many more in
clinical trials, there are not regulatory standards or compendial methods for in vitro
release testing of these type of dosage forms. However, several non-compendial
methods have been described in the literature [1, 2]. All these methods required
separation of the free drug from the colloidal particles before quantification which can be
challenging due to the small size of the carriers. Among the most commonly used
methods are: 1) the sample and separate method and 2) the dialysis method. In the
sample and separate method, the nanoparticulate dosage form is in the release media,
under constant temperature and constant agitation. Drug release is asses by sampling
the release media followed by ultrafiltration with centrifugation to recover only the free
drug. In the dialysis method, the nanoparticles are separated from the release media
though a dialysis membrane, the system is kept under constant temperature and
constant agitation and samples of free drug solution are taken from the reservoir across
the membrane, no additional separation steps are required. However, drug transport
through the membrane may delay the detection of released drug and provide and
inaccurate release profile. Release studies are usually performed at 37ºC to mimic
physiological temperature. Additional considerations include release media and
agitation. The type of release media depends on the intended site of administration and
site of action as well as drug solubility and stability, assay sensitivity, and the method
used. Sink conditions are preferable whenever possible. On the other hand, agitation is
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used to prevent nanoparticle aggregation and can be selected using physiological
considerations [3].
In vitro cytotoxicity in cancer cells can provide indirect information regarding drug
release from the nanoparticles. In order to kill cancer cells, free DOX needs to reach its
intracellular target: the cell nucleus. Therefore, the level of cell death depends on drug
release since encapsulated drug is completely inactive. We evaluated the cytotoxic
effect of Formulation 4 and Formulation 2 in A549 human lung cancer cells and
compared them with DOX-HCl and Doxil®. This cell line was considered pertinent
because small cell lung cancer is one of the clinical indications of DOX.
Due to their high surface: volume ratio and high surface energy, nanoparticles
tend to aggregate and settle; therefore long-term colloidal stability of nanoparticles is
challenging. In order to confer adequate stability, we introduced PEG into the structure
of the disulfide cholesterol-based copolymer PC5MA-SS-PEO. PEG’s hydrophilic nature
is intended to stabilize the nanoparticles through the short-range repulsive hydration
forces [4]. Having stable nanoparticles in suspension facilitates their use and translation
to the clinic so stability is an important property to evaluate when developing a
nanoparticle-based dosage form. In this particular case, we expect that the PEG in the
nanoparticles will provide optimal colloidal stability in long term storage. Stability of
Formulation 2 and Formulation 4 at 4ºC was evaluated in the present study over a 4month period.
In summary, the main objectives of this chapter were to 1) study the in vitro
performance of Formulation 2 and Formulation 4 and compare them to Doxil®, 2)
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confirmed the redox-sensitive nature of the carriers and 3) select the most promising
formulation for future in vivo studies based on in vitro testing results.

5.3. Methods
5.3.1. Materials
Doxorubicin hydrochloride (DOX-HCl) was purchased from Biotang Inc.
(Waltham, MA, USA). Triethylamine (TEA), acetonitrile (ACN), N,N-dimethylformamide,
polysorbate 80, acetic acid, sodium acetate, potassium chloride, sodium monobasic
phosphate, potassium dibasic phosphate and sodium chloride were purchased from
Fisher Scientific (Boston, MA, USA). Dimethylsulfoxide (DMSO), dithiothreitol (DTT),
chloroform (Chl) dichloromethane (DCM) and trifluoroacetic acid (TFA) were purchase
from Sigma-Aldrich (St Louis, MO, USA). 0.5% Trypsin and RPMI 1640 were purchased
from ThermoFisher Scientific (Waltham, MA, USA). Human lung cancer cell line (A549)
was purchased from the American Type Culture Collection (Manassas, VA, USA). Fetal
bovine serum (FBS) was purchased from Atlanta Biologicals (Norcross, GA, USA).
Commercially available Doxil® (Janssen, Horsham, PA) or equivalent doxorubicin
hydrochloride liposome (Dr. Reddy’s, Princeton, NJ) at a stock concentration of 2 mg/ml
were used as controls. Spectra/Pro dialysis membranes were obtained from Spectrum
Laboratories, 100Inc. (RanchoDominguez, CA, USA). Centrifugal filters were purchased
from Millipore (Darmstadt, Germany). All chemicals were either analytical or HPLC
grade.
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5.3.2. Preparation and characterization of DOX-SS-NPs
Formulation 2 and Formulation 4 were prepared as described in Chapter 4 of the
present document.

5.3.3. In vitro release of DOX from DOX-SS-NPs
We studied the in vitro release of DOX from Formulation 2 and Formulation 4
using a sample and separate method [3]. Nanoparticles equivalent to 100 µg of
doxorubicin were suspended in 10 ml of release media for a final concentration of 10
µg/ml which guaranteed sink conditions. Two types of release media were employed in
this study:
1) Release media pH 7.4: sodium phosphate buffer at a concentration of 0.01 M was
used to maintain a constant pH of 7.4. The osmolarity of the solution was adjusted to
guarantee isotonicity using sodium chloride. The release media also contained
polysorbate 80 at a w/v concentration of 0.1%.
2) Release media pH 5.0: sodium acetate buffer at a concentration of 0.1 M was used to
maintain a constant pH of 5.0. The osmolarity of the solution was adjusted to guarantee
isotonicity using sodium chloride. The release media also contained polysorbate 80 at a
w/v concentration of 0.1%.
Adjusting the pH of the release media to 7.4 intended to simulate conditions in
plasma and the cell cytoplasm while setting the pH to 5.0 intended to mimic the
conditions inside lysosomes where most nanoparticles accumulate after cell
internalization. To simulate intracellular reducing conditions, DTT at a concentration of
10 mM was added to the release media. This concentration equals that of intracellular
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GSH [5, 6]. The nanoparticle suspensions were incubated in a water bath at 37°C and
kept under constant agitation at 130 rpm. At selected time intervals (pH 7.4: 1, 4 and 8
h; pH 5.0: 1, 2, 4, 6, 8 and 24 h), 0.5 ml aliquots were removed from the release media,
and an equivalent volume of fresh media without nanoparticles was compensated so
the volume was kept constant at 10 ml during the duration of the study. Sampled
nanoparticles were not return to the release media. In that sense, total drug
concentration was different for each time point when calculating % cumulative drug
release, as described below:
% Cumulative drug release = Released drug (µg/ml) x 100%
Total drug (µg/ml)
- First time point
Total drug = 10 µg/ml
- Second time point
Total drug = (10 µg/ml) * 10 ml – (10 µg/ml) *0.5 ml = 9.5 µg/ml
10 ml
Ultrafiltration using a 100 kDa filter and centrifugation at 5000 rpm and 20°C for
20 min was used to separate released DOX from the nanoparticles. The collected
samples were stored at -20°C until analysis. DOX in the filtrate was quantified by HPLC
using the method described in chapter 4 of the present document, samples were diluted
1:5 or 1:10 with mobile phase before injection into the HPLC column.
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5.3.4. Stability of DOX-SS-NPs at 4°C
DOX-SS-NPs were adjusted to a concentration of 1 mg/ml (total mass). Samples
of 400 µl were stored in glass vials at 4°C. At different time points (2 weeks, 1, 2 and 4
months), samples were removed from the fridge and their particle size and drug loading
were measured and compared with the values obtained at day zero.

5.3.5. Cytotoxicity of DOX-SS-NPs in A549 human lung cancer cells
A549 human lung cancer cells (4000 cells/well) were seeded on 96-well plates
and cultured in 200 μl of RPMI supplemented with 10% FBS for 24 h at 37 °C and 5%
CO2. After incubation, media was removed and various concentrations of blank
nanoparticles (0.2−60 µg/ml), DOX-SS-NPs (Formulation 2 and Formulation 4), Doxil®
and DOX-HCl (0.02- 6 μg/ml of DOX equivalents) suspended in RPMI with antibiotics
were added to the cells. DOX-NPs, the non-cleavable formulation discussed in chapter
3 was also evaluated for comparison. After 72 h of incubation with the different DOX
formulations, cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-3,5diphenyltetrazolium bromide dye conversion (MTT dye, final concentration of 0.25
mg/ml). Media from the wells was removed and 100 µl of MTT dye dissolved in RPMI
without supplements were added to each well. Subsequently, plates were incubated for
4 h at 37 °C and 5% CO2 to allow the dye conversion to occur. Finally, the supernatant
from each well was removed and the precipitated dye crystals were dissolved in 200 µl
of DMSO. The absorbance of each well at 540 nm was determined using a microplate
reader (Tecan Group Ltd., Männedorf, Switzerland), using 690 nm as a reference
wavelength. Blank-redox sensitive nanoparticles used in this study were prepared
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according to the cosolvent removal method described in chapter 4 of the present
document.

5.3.6. Internalization of DOX-SS-NPs by A549 human lung cancer cells
To study cellular internalization, A549 cells were seeded at a density of 50,000
cells/well in an 8-well chamber slide and pre-incubated for 24 h at 37°C and 5% CO2.
Subsequently, media form each well was removed and 500 µl of serum-free RPMI
containing DOX-HCl, Doxil® or DOX-SS-NPs (Formulation 2 and Formulation 4) at an
equivalent DOX concentration (10 μg/ml) were added to each well, followed by
incubation for 4 h at 37 °C. DOX-NPs, the non-cleavable formulation discussed in
chapter 3 was also evaluated for comparison. Subsequently, cells were rinsed with PBS
and fixed with a 4% formaldehyde solution for 10 min followed by three washes with
PBS. After drying, cover glasses were put on top of the slides. Cellular uptake of DOXHCl, Doxil®, DOX-NPs and DOX-SS-NPs was imaged by confocal laser scanning
microscopy using a A1R spectral confocal microscope (Nikon, Tokyo, Japan) at an
excitation/emission wavelength of 490/558 nm.

5.3.7. Statistical Analysis
In vitro release profiles were compared by difference factor (f1) and similarity
factor (f2) analysis using the add-in program DDSolver [7]. For the cytotoxicity studies,
IC50 values were calculated using GraphPad Prism 8 software. All experiments were
conducted in at least three independent experimental replicates.
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5.4. Results and Discussion

5.4.1. In vitro release of DOX from DOX-SS-NPs
Release of DOX from redox-sensitive formulations and Doxil® was studied at pH
7.4 (plasma conditions) and pH 5.0 (lysosome conditions) using the sample and
separate method. This method was selected because higher free drug recovery was
observed in preliminary studies when comparing with the dialysis method. The main
objectives of this in vitro release study were: 1) assess the effect of the preparation
method on the release kinetics of the nanoparticles and 2) evaluate our initial
hypothesis that drug release from the nanoparticles would be faster in reducing
conditions. This particular in vitro release study was not conceived to establish and in
vitro/in vivo correlation. We focused on early time points since slow intracellular drug
release was the particular issue that we were trying to address by developing a redoxsensitive platform; generally, non-cleavable nanoparticles, including Doxil® , fail to
release a significant amount of DOX in the first 24 hours after being internalized by
cancer cells [8, 9]. Therefore, studying drug release between 0 – 24 hours was our
primary target.
To test the redox-sensitive character of the nanoparticles, DTT was incorporated
as a reducing agent in the release media. The possibility of DTT activity loss with
extended incubation time [9] was another reason for not conducting the in vitro release
studies beyond 24 hours.
On the other hand, due to DOX instability at pH 7.4 [11], the release study at this
pH was conducted for 8 h instead of 24 h so drug loss due to degradation was minimal.
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One of our main focus when studying drug release at pH 7.4 was to potentially assess
the risk of excessive burst release upon injection into the circulation and long incubation
periods were not required to answer this question. At pH 7.4, Formulation 2 and
Formulation 4, displayed a two-phase release profile with an initial burst release (0 -1 h)
followed by sustained release (1 h – 8 h) (Figure 5.1). During the burst release phase,
Formulation 2 released about 2.5% of the initial drug content while release from
Formulation 4 was closed to 14%. On the other hand, Doxil® released 20% of its drug
load in the same time period. These results suggest that burst release immediately after
injection may not be a big concern for our redox-sensitive formulations since in both
cases total burst release was less than that of the commercial reference product. Both
redox-sensitive formulations released less than 25% of the total drug content over an 8
hour period (Figure 5.1A). In both cases, drug release rates decreased over time, a
classic behavior of systems in which the concentration of drug molecules close to the
surface is depleted as time progresses [12] (Figure 5.1B). The initial release rate of
Formulation 4 was greater than the release rate of Formulation 2, suggesting that the
drug in Formulation 4 is in a region more accessible to the release media. These results
indicate that DOX release from Formulation 2 and Formulation 4 will be slow in plasmalike conditions which is important because it prevents high concentrations of free drug in
circulation that can potentially lead to toxicity in non-targeted organs.
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Figure 5.1. In vitro release of doxorubicin from redox-sensitive nanoparticles and Doxil®

at pH 7.4, 37◦C and 130 rpm. A) Cumulative release. B) Calculated Release rate. Data
are expressed as mean ± SD of three independent experimental replicates.

Drug release from Doxil® at pH 7.4 was faster than release from the redoxsensitive formulations, being 34% of the initial content released after 8 hours. The
presence of a reducing agent in the media, slightly increased the release rates for both
redox-sensitive formulations at early time points (Figure 5.1B). However, release in
reducing conditions was not greater than 30% of the initial drug content in the
nanoparticles for both formulations after 8 hours (Figure 5.1A). DOX release from Doxil®
under reducing conditions did not displayed a clear trend when compared to release in
non-reducing conditions (Figure 5.1A).
On the other hand, at pH 5.0, for all formulations, release rates increased
compared to pH 7.4 (Figure 5.2A). Being a weak base with pKa 7.2 – 8.2 [13, 14], the
solubility of DOX and its partition into the aqueous phase augment as pH decreases,
explaining faster release at lysosome-like conditions. Release at pH 5.0 also displayed
a biphasic profile in both redox-sensitive formulations; being release from Formulation 4
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faster than release from Formulation 2. Formulation 2 displayed very little burst release
(less than 10% after 1 hour) while burst release from Formulation 4 was substantial
(more than 20% after 1 hour). Burst release at pH 5.0, inside the lysosome, will provide
free drug available to reach the intracellular target rapidly after internalization by cancer
cells. Faster drug release from Formulation 4 suggests that in this formulation drug
molecules can be located in areas closer to the surface of the nanoparticles while in
Formulation 2 drug molecules may be restricted to inner parts of the core, making their
transfer to the release media slow. Differences in the zeta potential values for both
formulations (Formulation 4 +3.4 mv; Formulation 2 -1.7 mv) indicate a potential
interaction of drug molecules (a protonated and positively charged fraction) with the
slightly anionic PEG segments in the case of Formulation 4. In this formulation, drug
molecules in the PEG shell region can be easily transferred to the release media
explaining faster drug release and greater burst release in Formulation 4.
At pH 5.0 as well as pH 7.4, the redox sensitive formulations displayed a release
profile in agreement with monolithic or matrix-type devices where the drug is
homogenously dispersed in the polymeric matrix. These type of devices generally
exhibit an initial burst release from the surface and release rate decreases over time as
the distance that the drug molecules have to cover to reach the release media
increases with time [15]. Similarly to what was observed at pH 7.4, under non-reducing
conditions release from Doxil® was faster than release from any of the redox-sensitive
formulations. The addition of a reducing agent accelerated drug release from
Formulation 2 and Formulation 4 (Figure 5.2). On the contrary, drug release from
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Doxil®, at pH 5.0, did not change in a reducing environment, highlighting the specificity
of the drug release mechanism from DOX-SS-NPs.
We used the difference factor and similarity factor analysis to identify differences
in the release profiles of Formulation 2 and Formulation 4 at pH 5.0. Regardless of the
reducing status of the media, f1 was bigger than 15 and f2 was below 50, indicating that
the compared release profiles were not equivalent. In other words, release from
Formulation 4 was significantly faster than release from Formulation 2 in both reducing
and non-reducing conditions. Interestingly, the use of different methods for the
preparation of Formulation 2 and Formulation 4 led to marked differences in the in vitro
drug release profile, likely due to differences in the distribution of the drug molecules in
the nanoparticles. This finding underscores the importance of evaluating different
preparation methods when developing drug-loaded nanoparticles from amphiphilic block
copolymers. The same analysis was conducted to determine the effect of the
introduction of a reducing agent in the release media. For both formulations
(Formulation 2 and Formulation 4), the release profiles significantly changed under
reducing conditions, confirming that drug release from these nanoparticles can be
selectively triggered under reducing conditions.
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Figure 5.2. In vitro release of doxorubicin from redox-sensitive nanoparticles and Doxil®
at pH 5.0, 37◦C and 130 rpm. A) Cumulative release. B) Data are expressed as mean ±
SD of three independent experimental replicates.

Drug release is a kinetic process, therefore, the change in release rate over time
can give us an idea of its order respect to drug concentration in the nanoparticles and
the driving forces behind the process. For both redox-sensitive formulations, drug
release rates decreased exponentially over time (Figure 5.2B), in agreement with a first
order process in which concentration gradient is an important driving force for drug
release. After the initial burst release phase (0 -1 h), the release profiles of the redoxsensitive nanoparticles, fitted a first order kinetic model in which release rate depends
on the remaining amount of drug in the nanoparticles [15] (Figure 5.3):
Q = 100(1-e-kt) or the linear form ln(100 - Q) = ln100 – kt
Where Q is the cumulative release percentage, k is the release rate constant and t is
the time (h).
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Release constants were calculated using the linear form of the model (Table 5.1).
Constants increased when a reducing agent was present in the media and this increase
was statistically significant for Formulation 4. In the case of Doxil®, release did not fit the
model described above and therefore a release constant was not calculated.
Table 5.1. Calculated in vitro release constants

b

2

k (h )

R

Formulation 2

0.0105 ± 0.004

0.9812

Formulation 2 DTT

0.0162 ± 0.005

0.9238

Formulation 4

0.0114 ± 0.001

0.9631

Formulation 4 DTT
a

-1

Formulation

a,b

0.0317 ± 0.009

0.9805

Release constant is significantly different from the release constant of Formulation 2.
Release constant is significantly different from the release of Formulation 4.
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Based on the first order model described above, we calculated the time it would
take for each formulation to achieve 99% drug release; 18 days in the case of
Formulation 2 that can be reduced to 11 days under reducing conditions and 16 days
for Formulation 4 that get reduced to 6 days in the presence of DTT. These calculations
highlight the role of redox-triggered strategies on facilitating fast and complete drug
release from nanoparticles.

5.4.2. Stability of DOX-SS-NPs at 4°C
The stability of Formulation 2 and Formulation 4 at 4ºC was evaluated over a 4month period. Formulation 2 displayed colloidal stability up to 2 months; after 4 months,
an increased in both the average particle size and the PDI was observed (Figure 5.4A).
On the contrary, Formulation 4 displayed adequate colloidal stability across the duration
of the study (Figure 5.5A). Regarding drug stability, both formulations preserved above
95% of the original drug content up to 2 months in storage but after 4 months, drug
content felt to 91.4% and 83.0% for Formulation 2 and Formulation 4 respectively
(Figures 5.4B and 5.5B). As mentioned before, pH plays a key role in the stability of
DOX. For example, in the commercial form of DOX-HCl solution the pH is adjusted to
3.0 since it is known that the stability of DOX improves at low pH. The fact that pH was
not controlled in this stability study, potentially ranging from 6.5 – 7.0 may have been a
source for drug instability. Further efforts to improve the long term stability of these
redox sensitive formulations may include pH control and lyophilization.
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Figure 5.4. Storage stability of Formulation 2 at 4ºC. A) Colloidal stability. B) Drug
content over time. Data are expressed as mean ± SD of three independent
experimental replicates.

Figure 5.5. Storage stability of Formulation 4 at 4ºC. A) Colloidal stability. B) Drug
content over time. Data are expressed as mean ± SD of three independent replicates.
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5.4.3. Cytotoxicity of DOX-SS-NPs in A549 human lung cancer cells
Significant differences were observed when comparing the cytotoxic activity of
Formulation 2 and Formulation 4 in A549 human lung cancer cells (Figure 5.6A). At
equivalent DOX concentrations, Formulation 4 killed more cells than Formulation 2.
These discrepancies can be a consequence of their differences in terms of drug
release; the formulation with fastest drug release was subsequently more efficacious in
vitro. Blank nanoparticles with no loaded drug did not affect cell viability, therefore, the
cytotoxic activity observed for Formulation 2 and Formulation 4 is entirely due to the
presence of doxorubicin. Being Formulation 4 the most cytotoxic of the redox-sensitive
formulations, we compared its activity to DOX-HCl and Doxil® in terms of in vitro
anticancer effect (Figure 5.6B). As expected, DOX-HCl displayed the greatest cytotoxic
activity, being molecular DOX a compound with high cell membrane permeability that
quickly reaches its intracellular target it is usually the most potent form of the drug in
vitro. Formulation 4 was slightly but significantly more cytotoxic than Doxil®, as denoted
by their respective IC50 values (Table 5.2). Formulation 4 was also significantly more
cytotoxic than DOX-NPs, the non-cleavable nanoparticles studied in chapter 3,
indicating improvement compared to the first type of cholesterol-based nanoparticle
developed in the laboratory (chapter 3).
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Table 5.2. IC50 values for different doxorubicin formulations
Formulation

IC50 (ng/ml)

95% CI (ng/ml)a

DOX-HCl

56.8

40.3 - 80.1

Doxil®

627.8

462.6 - 852.1

Formulation 2

1212

921.3 - 1596

Formulation 4

250.8

213.5 - 294.6

DOX-NPs

1757

1416 - 2181

a

Non-overlapping 95% CIs denotes statistically significant differences between
formulations.
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5.4.4 Internalization of DOX-SS-NPs by A549 human lung cancer cells
Four hours after the addition of DOX-HCl to the cell culture most of the
fluorescent signal localized in the nucleus of the cells (Figure 5.7). Rapid diffusion of
free DOX across the cell membrane and subsequent translocation into the cell nucleus
have been extensively reported [16, 17], although it is unclear if the drug is transported
to this organelle by passive diffusion or by carrier-mediated transportation [18].
Depending on the drug concentration, nuclear accumulation of DOX can be 2 - 4 times
higher than the accumulation in other regions of the cells [17, 19], this particular
distribution is facilitated by the strong interaction between DOX and DNA; the
anthracycline ring in DOX intercalates into the DNA base pairs forming complexes with
the adenine-thymine and the guanine-cytosine regions respectively [20]. In the case of
the redox sensitive formulations, interesting differences in the intracellular distribution of
DOX were found. When cells were exposed to Formulation 2, DOX was detected mainly
in the cytoplasm of the cells, suggesting effective nanoparticle internalization but
minimal release. In the case of Formulations 4, fluorescence signal was found in the
cytoplasm, indicating nanoparticle internalization, as well as in the cell nucleus,
suggesting rapid drug release since nanoparticles are too big to cross the nuclear pores
and accumulate as intact carriers in the nucleus so only free drug can be detected in
this organelle (Figure 5.7). These results seemed to agree with the results of the in vitro
release study; since Formulation 4 releases the drug significantly faster than
Formulation 2 drug delivered by Formulation 4 reaches the cell nucleus faster than drug
delivered by Formulation 2. Formulation 4 seemed to overcome the slow drug release
and subsequent absence of doxorubicin in the cell nucleus observed with DOX-NPs, the
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first type of cholesterol-based nanoparticle developed in the laboratory (chapter 3). No
fluorescence signal was detected in cells exposed to Doxil®. Seynhaeve et al also
reported little intracellular internalization of Doxil® at early time points (0 – 3 h)
compared to DOX-HCl. The authors in this paper stated that in the first three hours of
exposure the majority of Doxil® appeared loosely adhered to the membrane, being
washed away upon medium change so that longer incubation times were required to
observe intracellular Doxil® at the same imaging conditions used for DOX-HCl [7]. Our
observation then seems to be a true representation of the slow internalization of Doxil®
in cancer cells. As a consequence, rapid nuclear accumulation of DOX when
administered Doxil® does not occur.
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Figure 5.7. Intracellular distribution of DOX delivered by different formulations. TM
stands for transmitted light. Scale bars represent 20 µm.

5.5 Conclusions
After comprehensive in vitro evaluation, the redox-sensitive nature of
nanoparticles prepared with PC5MA-SS-PEO was confirmed by increased in vitro drug
release in reducing conditions. Additionally, significant differences in the rate and extent
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of the in vitro drug release, the cytotoxic activity in cancer cells and the intracellular
distributions of DOX were observed between Formulation 2 and Formulation 4,
suggesting that the method of preparation can not only affect the properties of drugloaded nanoparticles but also their performance.
On the other hand, results from the cytotoxicity study and the intracellular drug
distribution study indicate that the redox-sensitive nanoparticles overcame the issue of
slow release associated with DOX-NPs, the non-cleavable nanoparticles evaluated in
chapter 3.
Due to faster drug release and greater cytotoxic activity, Formulation 4 seems to
be the best candidate to advance to in vivo efficacy and toxicity studies, however,
concerns regarding the effect of particle size in tumor accumulation require that a
comparative biodistribution study is conducted before selecting the final formulation.
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Chapter 6.
Assessment of the Biodistribution, In vivo Safety and Efficacy of a Cholesterolbased Polymeric Nanoparticle Formulation for Bioresponsive Release of
Doxorubicin in Tumor Cells
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6.1. Abstract
This chapter describes the comparison, in terms of in vivo distribution, between
two redox-sensitive formulations (Formulation 2 and Formulation 4) in order to select
the best candidate for in vivo efficacy studies. Subsequently, the process of dose
selection for DOX-SS-NPs, DOX-HCl and Doxil®, based on tolerability studies in healthy
SCID mice is depicted, as well as the results regarding the effects of DOX-HCl, Doxil®
and DOX-SS-NPs on tumor growth and survival of tumor-bearing SCID mice. Overall,
DOX-SS-NPs effectively accumulated in tumor tissues while no accumulation
differences between Formulation 2 and Formulation 4 were found. Encouraging results
regarding tumor growth inhibition when treating tumor bearing mice with DOX-SS-NPs
were observed as well as significant improvement in the safety profile compared to the
free form of the drug.

6.2. Introduction
DOX is a potent and commonly used cytotoxic anticancer drug with severe and
dose-limiting side effects. The administration of DOX can cause chronic heart damage,
myelosuppression, hepatotoxicity and alterations in the epithelium of the intestine
among other multi-organ side effects [1]. Safer and effective alternatives to conventional
doxorubicin hydrochloride (DOX-HCl), the soluble non-encapsulated form of DOX, have
been of great interest in order to reduce the risk of life-threatening adverse reactions
and extend doxorubicin use to high-risk populations such as patients with pre-existing
cardiac conditions. In 1995, the FDA approved a pegylated liposomal formulation of
DOX, commercially known as Doxil®, for the treatment of Kaposi sarcoma, a type of
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cancer produced by a viral infection and common among HIV-infected patients. Since
then, the indications of Doxil® have expanded to ovarian cancer and multiple myeloma.
In terms of tolerability, the use of Doxil® reduces the incidence of cardiac toxicity (when
compared to DOX-HCl) and myelosuppression [2]. Despite this superiority, Doxil® can
induce unique and dose-limiting side effects; 1) desquamating dermatitis, known as
palmar plantar erythrodysthesia (PPE) or “foot and hand syndrome” and 2) a type of
acute hypersensitivity denominated complement activation-related pseudo-allergy
(CARPA) [3]. These side effects, particularly PPE, limit the maximum dose of Doxil® that
can be administered to 50 mg/m2 IV every 4 weeks which does not translate into
superior efficacy when compared to the standard of care [2].
Given the need for safer and especially more efficacious alternatives to DOX-HCl
and Doxil®, we previously demonstrated that the encapsulation of DOX into cholesterolbased polymeric nanoparticles reduced the toxicity of the drug while preserving some of
the anti-tumor activity (see chapter 3 of the present document). Subsequently, we
incorporated a disulfide bond in the polymer structure to facilitate drug release and
potentially improve the efficacy of these novel nanomedicines. After extensive
optimization and in vitro evaluation of different redox-sensitive formulations, two
promising candidates were identified: Formulation 2 and Formulation 4. The objectives
of this chapter were to 1) select a final redox-sensitive formulation based on the in vivo
distribution of the nanoparticles and 2) evaluate the in vivo safety and efficacy of this
selected formulation in comparison to DOX-HCl and Doxil®.
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6.3. Methods

6.3.1. Materials
Doxorubicin hydrochloride (DOX-HCl) was purchased from Biotang Inc.
(Waltham, MA, USA). Triethylamine (TEA), acetonitrile (ACN), N,N-dimethylformamide
and sodium chloride were purchased from Fisher Scientific (Boston, MA, USA).
Dimethylsulfoxide (DMSO), dichloromethane (DCM) and trifluoroacetic acid (TFA) were
purchase from Sigma-Aldrich (St Louis, MO, USA). Draq5, 1,1′-dioctaecyl-3,3,3′,3′tetramethylindotricarbocyanine iodide (DiR) was obtained from Invitrogen (Carlsbad,
CA, USA). Trypsin (0.5%) and RPMI 1640 were purchased from ThermoFisher
Scientific (Waltham, MA, USA). A549 human lung cancer cell line was purchased from
the American Type Culture Collection (Manassas, VA, USA). Fetal bovine serum (FBS)
was purchased from Atlanta Biologicals (Norcross, GA, USA). Commercial Doxil®
(Janssen, Horsham, PA) or doxorubicin hydrochloride liposome (Dr. Reddy’s, Princeton,
NJ) at a stock concentration of 2 mg/ml were used as controls. Spectra/Pro dialysis
membranes were obtained from Spectrum Laboratories, 100Inc. (RanchoDominguez,
CA, USA). Centrifugal filters were purchased from Millipore (Darmstadt, Germany). All
chemicals were either analytical or HPLC grade.

6.3.2. In Vivo Biodistribution of DiR-SS-NPs
All animal studies were performed according to an approved protocol by
Institutional Animal Care and Use Committee (IACUC) at the University of Connecticut.
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The biodistribution of nanoparticles formed by PC5MA-SS-PEO was assessed by
in vivo near-infrared (NIR) imaging. A NIR fluorophore, DiR, was incorporated into the
nanoparticles by the cosolvent removal or the O/W emulsion method to obtain
nanoparticles with similar characteristics to Formulation 2 and Formulation 4. For
nanoparticles prepared by the cosolvent removal method, 3 mg of redox-sensitive
polymer were weighted and dissolved in 1.5 ml of DMF using bath sonication. 90 µl of a
solution of DiR in DMF (2 mg/ml) were added to the polymer solution followed by
vortexing. The solution of polymer and dye in organic solvent was added to 2 ml of
ultrapure water in a dropwise manner under vigorous agitation (700 rpm). The mixture
was stirred for 1 hour at room temperature. Then, the mixture was transferred to a
dialysis bag (MWC: 12 kDa) and dialyzed against ultrapure water for 48 hours (3 water
changes total). For nanoparticles prepared by the O/W emulsion method, 75 µl of a DiR
stock in DMF (2 mg/ml) were added to 625 ul of dichloromethane. This mixture was
added in a dropwise manner to a suspension of blank-SS-NPs in water (0.5 mg/ml, 5 ml
total) under vigorous agitation (700-800 rpm). Vortexing during the addition to facilitate
mixing. Once the addition was completed, probe sonication (2 minutes, 20% amplitude)
was used to promote emulsion formation. Dichloromethane was evaporated by stirring
the emulsion overnight. Regardless the method of preparation, nanoparticle
suspensions were collected and centrifuged at 8000 rpm for 10 minutes to eliminate
insoluble dye. Subsequently, suspensions were filtered through a 0.45 µm filter. The
DiR content of was determined by absorbance at 750 nm.
To obtain an in vivo tumor model, SCID female mice, 8 week old, were implanted
subcutaneously with 2 million A549 cells in the right hind leg. Tumor growth was
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monitored twice a week. The study was conducted 4 weeks after tumor cell
implantation. Mice were imaged before injection for background signal. Subsequently,
100 µl of the DiR-SS-NPs adjusted to a concentration of 20 µg/ml (DiR equivalents)
were administered to each mice through tail vain injection (final DiR dose 2 µg/mouse).
Images were taken right after administration and then 1, 6, 24, 48 and 72 h after
injection. At time points 6 h, 24 h and 72 hours, mice were euthanized and major organs
(heart, lung, spleen, liver, kidneys and tumors) were collected and imaged.

6.3.4. In Vivo Dose Tolerability of DOX-SS-NPs
This study was conducted to determine the effect of repetitive administrations of
DOX-SS-NPs in SCID mice at a dose toxic when administering DOX-HCl but potentially
safe when administering DOX-SS-NPs. A dose of 3 mg/kg was selected based on our
previous experience as well as literature reports [4, 5]. Adult healthy SCID mice (4
mice/group) were treated once a week with Doxil® or DOX-SS-NPs (Formulation 4)
equivalent to 3 mg/kg of DOX via tail vein injections. Due to high toxicity at the site of
injection that prevents frequent i.v administration of DOX-HCl mice in this group were
injected intraperitoneally. Previous studies have reported similar plasma and liver
concentrations of DOX after i.v and i.p administration in nude mice even though
concentrations in other organs like heart and muscle may be affected by the route of
administration [6]. Blank redox-sensitive NPs and saline solution were given i.v as
controls. Body weight was monitored twice a week and a total of six doses were
administered. At the end of the study mice were euthanized and relevant organs such
as heart, lungs, liver, spleen and kidneys were collected and fixed with 4%
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formaldehyde in PBS for histopathological analysis. DOX-SS-NPs (Formulation 4) were
prepared as described in chapter 4 of the present document. Blank-redox sensitive
nanoparticles were prepared using the cosolvent removal method described in chapter
4 of the present document.

6.3.5. In Vivo Efficacy and Safety of DOX-SS-NPs
The antitumor activity of DOX-HCl, Doxil® and DOX-SS- NPs was evaluated in
tumor bearing SCID mice inoculated subcutaneously in the right flank with 2 × 106 A549
cells. When the tumors grew to an average volume between 20 - 30 mm3, mice were
divided into four treatment groups so the average tumor volume in each group was the
same (n = 4 - 5): 1 mg/kg DOX-HCl, 3 mg/kg Doxil®, 3 mg/kg DOX-SS-NPs and saline.
Mice treated with Doxil®, DOX-SS- NPs and saline were injected intravenously while
DOX-HCl was administered intraperitoneally. Treatment was given once a week for 7
weeks. The day of the first dose was designated as day 0. Tumor size and body weight
were monitored three times per week. At the end of the study, mice were euthanized
and serum and major organs were collected for pathology and biochemical analysis.

6.3.6. TUNEL assay staining
Tumor tissues from the efficacy study were sent to the University of Connecticut
Health Center Research Histology Core for terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) staining. Subsequently, images taken with a 4X objective
were stitched and analyzed to reconstruct the entire tumors [7] and analyzed for %
stained area using a default algorithm in Image J for thresholding.
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6.3.7. Alanine aminotransferase (ALT) assay
ALT plasma levels were determined as a biomarker for liver damage in mice from
the efficacy study. Infinity ALT Liquid Stable Reagent (Thermo Fisher Scientific Inc.,
Waltham, MA) was used to determine ALT activity. Briefly, 100 µl of reagent was added
to 10 µl serum or plasma samples, and absorbance was measured
spectrophotometrically at 340 nm using a Bio-Tek Power Wave X Spectrophotometer.
ALT activity (U/l) was determined using the molar extinction coefficient of NADH (6.3
mM−1 cm−1).

6.3.8 Statistical Analysis
Analysis of variance and survival curve analysis were performed using GraphPad
Prism 8 software (GraphPad Inc., San Diego, CA). All experiments were conducted in at
least three independent experimental replicates and p-values < 0.05 were considered
significant.

6.4. Results

6.4.1. In Vivo Biodistribution of DiR-SS-NPs
DiR-SS-NPs prepared by cosolvent removal method had a Z-average of 89.7 nm
and a PDI of 0.216 while nanoparticles prepared by the O/W emulsion method
displayed a Z-average of 168.7 nm and a PDI of 0.101. The size distribution of DiR-SSNPs resembled Formulation 2 and Formulation 4 respectively. In consequence, DiR-SSNPs were used as surrogates for the biodistribution study. For both formulations, liver
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accumulation was observed early after injection. As time progressed, fluorescence
signal was detected in tumors, being 24 h the time point when maximum intensity was
observed. (Figure 6.1 and Figure 6.2).

Figure 6.1. In vivo distribution of DiR-SS-NPs prepared by the cosolvent removal
method (Formulation 2). Tumor location is highlighted in red.
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Figure 6.2. In vivo distribution of DiR-SS-NPs prepared by the O/W emulsion method
(Formulation 4). Tumor location is highlighted in red.

Signal from removed organs at 24 and 72 hours confirmed the results observed
in vivo; for both formulations the liver was the organ with the greatest nanoparticle
accumulation (60% - 80% of total recovered signal), followed by the spleen (10% - 30%)
and the lungs (5% - 10%) (Figure 6.3). Nanoparticle accumulation was observed in
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removed tumor tissues at 24 and 72 h, being the intensity approximately 2% of the total
recovered signal (Figure 6.4).

Figure 6.3. Organ-specific distribution of DiR-SS-NPs, 24 h after injection. Data are
plotted as mean ± SD of three replicates. % Total signal = (Individual organ radiant
efficiency per area/Total recovered radian efficiency per area)*100%.

No differences in terms of tumor accumulation were observed between
Formulation 2 and Formulation 4. Considering the results from the in vitro evaluation
and biodistribution, Formulation 4 seemed more promising and therefore was selected
for the in vivo efficacy and toxicity studies. Formulation 4 will be denoted as DOX-SSNPs in the subsequent text.

119

Figure 6.4. Accumulation of DiR-SS-NPs in subcutaneous tumors. A) Fluorescent
signal from DiR-SS-NPs in collected tumors. B) Quantification of Fluorescent signal
from DiR-SS-NPs in collected tumors, 24 h after injection, expressed as percentage of
total recovered signal. Data are plotted as mean ± SD of three independent replicates.

6.4.2. In Vivo Tolerability of DOX-SS-NPs
In order to established if a dose of 3 mg/kg DOX-SS-NPs (DOX equivalent) will
be tolerated in repeated administrations, healthy mice were given weakly doses of 3
mg/kg DOX-HCl, Doxil® and DOX-SS-NPs while saline and blank nanoparticles were
given as controls. A total of 6 doses were administered and body weight was monitored
twice a weak.
Early in the study, mice treated with DOX-HCl exhibited signs of toxicity such as
significant weight loss compared to the saline group (Figure 6.5A), hunched posture,
ruffled fur coats, and low activity; all the mice in this group died by day 20 of the study.
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Mice treated with Doxil® showed significant weight loss, compared to the saline group,
close to the end of the study. One of the mouse in this group experienced eye damage
after two doses; ocular adverse reactions like dry eye and conjunctivitis have been
reported in the post-marketing surveillance of Doxil® [8] but it is difficult to known if this
finding is related to the treatment. This mouse also developed diarrhea followed by
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weight loss and dead. In contrast, no adverse effects were observed in mice treated
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Figure 6.5. Tolerability of 3 mg/kg DOX-SS-NPs in healthy SCID mice. All mice
received 3 mg/kg DOX equivalents regardless of the administered formulation (n = 4).
A) Effect on body weight. #Statistically significant differences between DOX-HCl and
saline group, Kruskal-Wallis test, p < 0.05. *Statistically significant differences between
Doxil® and saline group, Krustal-Wallis test, p < 0.05). B) Effect on survival. *Statistically
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significant differences between DOX-HCl and the saline control group, Gehan-BreslowWilcoxon test, p < 0.05.

By the end of the study, survival among groups was 0% for DOX-HCl, 75% for
Doxil® and 100% for DOX-SS-NPs, Blank NPs and saline (Figure 6.5B). Only the
survival curve of the DOX-HCl group was significantly different from the survival curves
of the other treatment groups (Figure 6.5B). It is known that SCID mice are very
sensitive to the toxic effects of DOX, causing dead at low accumulative doses ranging
from 6 mg/kg to 12 mg/kg [4, 5]. Our results agreed with these reports. In our case, all
mice died when the accumulative dose of DOX-HCl reached 9 mg/kg. Even though
Doxil® is less toxic than DOX-HCl, a previous study observed some toxicity in SCID
mice at a weekly dose of 3 mg/kg [4]. Accordingly, we observed toxicity in one out of
four mice treated with Doxil® and despite lack of statistical significance, the fact that no
toxicity was observe in any of the mice treated with DOX-SS-NPs suggests than our
formulation could be potentially safer than Doxil®. Regarding the histopathology
analysis, liver toxicity was a concern for the group treated with DOX-SS-NPs due to
high glutathione levels in this organ. However, the livers of all mice in the study were
normal. No evidence of heart, lung or kidney toxicity was found in any group in the
study. A severe reduction in spleen hematopoiesis occurred in one of the mice treated
with DOX-HCl (3 doses of 3 mg/kg) while a moderate reduction was observed in one of
the mice treated with DOX-SS-NPs (6 doses of 3 mg/kg). Despite causing fatal toxicity
in all the treated mice, organ-specific toxicity that could explain dead was not observed
in mice treated with DOX-HCl. Besides cardiac toxicity and myelosuppression, DOX-
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HCl can also induce severe intestinal damage [9]. Being weight loss one of the side
effects observed in the DOX-HCl-treated group, it is possible that intestine toxicity was
the cause of death in these mice, which could not been confirmed in the pathology
analysis since intestine samples were not collected. Overall, DOX-SS-NPs at a dose of
3 mg/kg, once a week, could be administered to healthy mice for at least 6 weeks
without inducing marked toxicity, therefore, it was decided to use the same dose in the
subsequent efficacy study.

6.4.2. In Vivo Efficacy of DOX-SS-NPs
Tumor-bearing SCID mice received 7 weekly doses of 3 mg/kg DOX-equivalents
of Doxil® or DOX-SS-NPs. Mice in the DOX-HCl group received 7 weekly doses of 1
mg/kg because it was previously observed that a dose of 3 mg/kg DOX-HCl was very
toxic for repeated administrations. By the end of the study, the average tumor volume
was 1301.0 mm3 for the saline group, 908.3 mm3 for the DOX-HCl group, 488.3 mm3 for
the DOX-SS-NPs group, and 437.8 mm3 for the group treated with Doxil® (Figure 11A).
(Figure 6.6A).
When comparing tumor growth between groups, statistically significant
differences between the saline group and both the DOX-SS-NPs and the Doxil® group
were found by the end of the study (Figure 6.6B). The inhibitory effect of DOX-SS-NPs
and Doxil® was also observed in the size and weight of tumors collected by the end of
the study (Figure 6.7). No significant differences were observed between the DOX-SSNPs and the Doxil® treatment. However, it is important to consider that the lack of
significant differences may be due to large variation and small sample size.
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Regarding tumor cell death, there were not statistically significant differences
among groups when analyzing TUNEL staining; overall, tumors were very big by the
end of the study and displayed large areas of cell death, even those in the saline group
(Figure 6.8).
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Figure 6.6. Effect of 3 mg/kg DOX-SS-NPs (Formulation 4) on tumor growth. A) Tumor
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Figure 6.7. Effect of 3 mg/kg DOX-SS-NPs (Formulation 4) on tumor weight and size.
A) Tumor weight (n = 3 – 4). B) Picture of tumors collected at the end of the study.
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Figure 6.8. %Tumor area positive for TUNEL staining. Data are expressed as mean ±
SD of three independent replicates.

In terms of treatment safety, mice in the DOX-HCl group displayed significant
weight loss, compared to mice in the saline group, after only 3 doses, and their weight
loss progressed up to the end of the study. Mice in the DOX-SS-NPs group also
experienced weight loss but only after receiving 6 doses of the treatment and it was not
statistically significant (Figure 6.9A). By the end of the study, survival among the groups
was 80% (4/5) for saline, 60% (3/5) for DOX-HCl, 75% (3/4) for Doxil® and 100% (4/4)
for DOX-SS-NPs, being the treatment with DOX-SS-NPs the only one providing 100%
survival (Figure 6.9B).
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Figure 6.9. Tolerability of 3 mg/kg DOX-SS-NPs (Formulation 4) in tumor-bearing SCID
mice. (n = 4-5). A) Effect on body weight. *Statistically significant differences between
DOX-HCl and saline group (Kruskal-Wallis test, p < 0.05. B) Effect on survival.

Results from the pathology analysis are summarized in Table 6.1. All mice
treated with DOX, regardless of the form, displayed myelosuppression and splenic
hemosiderosis secondary to hematopoietic toxicity. Splenitis, manifested as
accumulation of neutrophils in the spleen, was observed in all DOX-treated mice except
from one mouse in the Doxil® group. Liver atrophy was also a common finding in DOXtreated mice. This atrophy was characterized by smaller hepatic lobules, smaller
hepatocytes and depletion of glycogen from the hepatocyte cytoplasm. Since neither
liver necrosis not fibrosis or inflammation were observed, it is believed that liver atrophy
could be secondary to the weigh lost and overall emaciation of the mice; once the
glycogen reserves in the liver are consumed, hepatocyte size and morphology change,
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which could explain the observed atrophy of the organ. Interstitial pneumonia was found
in some DOX-treated mice. In the case of the DOX-HCl and DOX-SS-NPs groups,
interstitial pneumonia could be secondary to lung metastasis because both are
simultaneously present. Mice treated with Doxil® also developed interstitial pneumonia
but there were not tumors present in the lungs of these mice. It is possible that this is an
acute finding produced by anesthesia. On the other hand, lung toxicity, although not
predominant, has indeed been reported in patients treated with pegylated liposomal
DOX [10, 11], in some cases resulting in lethal toxicity. However, the absence of lung
necrosis or fibrosis makes unlikely that interstitial pneumonia was produced by Doxil®.
One mouse in the Doxil® group displayed myocarditis and pulmonary arteritis while no
sign of heart toxicity were found in mice treated with DOX-SS-NPs or DOX-HCl. The
fact that a lower dose of DOX-HCl was used (1 mg/kg) in this study, compared to a
higher dose of Doxil® and DOX-SS-NPs (3 mg/kg), may explain why cardiac damage
was not observed in the DOX-HCl group. Finally, moderate enterocolitis was observed
in one of the mice treated with DOX-SS-NPs but it is unclear if it was produced by the
treatment of it was due to an unrelated infection. The hypothesis derived from the
tolerability study that intestine damage could be the cause of rapid weight loss and
death was not confirmed by the pathological analysis since not intestine damage was
found.
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Table 6.1. Pathologic findings in tumor-bearing mice treated with different forms of DOX
Pathologic Findings

Mouse

Treatment

01

Splenic
Hepatic
Lung
Interstitial
Myelosuppression hemosiderosis Splenitis atrophy metastasis pneumonia Miocarditis
N

N
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Y (1)
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Y (3)

Y (3)
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Y
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N

N

Y (4)
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N

N

N

Y

N

Y (4)

Y (4)

Y (2)

N

N

Y

Y

Y (1)

Y (4)

Y (2)

Y (1)

N

Y

N

Y (4)

Y (4)

Y (2)

Y (2)

Y

Y

N

Y (4)

Y (4)
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N
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Y (4)
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Y (2)
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N

N

N
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Saline

DOX-HCl
1 mg/kg

22
02
03

®

Doxil
3 mg/kg

16
06
14
15

DOX-SS-NPs
3 mg/kg

a

Lesions were scored according to the following scale: (1) minimal, (2) slight, (3)
moderate, (4) market and (5) severe.

Discrepancies in terms of organ-specific effects were observed between the
tolerability study in healthy mice and the efficacy study in tumor-bearing mice, almost no
toxicity was observed in the first while the former lead to multiple organ alteration
findings, especially when looking at the DOX-SS-NPs and Doxil® groups which received
the same dose in both studies. One potential explanation is that i.v injections were very
difficult to perform in the tolerability study since they have to be done inside a chemical
safety cabinet and it took some initial doses to perfect the technique. It is possible that
mice in the tolerability studied received lower actual doses than mice in the efficacy
study where there were not injection problems.
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ALT values increased in mice treated with Doxil® and DOX-SS-NPs, compared to
the saline group, however, differences were only significant for the latest group (Figure
6.10). Since only organs and blood from surviving mice were taken for analysis, the
toxic effects leading to the death of mice in the DOX-HCl and Doxil® groups are
unknown and results can be bias because they correspond to the mice that experienced
less toxicity while in the case of DOX-SS-NPs because there were not deaths we have
a complete picture of the toxic effects induced by this treatment.

Figure 6.10. Serum ALT levels in tumor-bearing mice treated with 3 mg/kg DOX-SSNPs. ALT is expressed as international units (IU) per liter, data are plotted as mean ±
SD of three independent replicates. *Significant differences between 3 mg DOX-SSNPs and saline, ANOVA test, p < 0.05.
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Survival data and the absence of cardiac damage in mice treated with DOX-SSNPs suggests that DOX-SS-NPs at a weekly dose of 3 mg/kg was less toxic than the
same dose of Doxil®. However, a study with a larger sample size will be required to
establish statistically significant differences among groups.

6.5. Conclusions
After extensive formulation development and in vitro testing work, the particular
goals of this part of the dissertation were to 1) select a final redox-sensitive formulation
from two candidates, based on the in vivo distribution of the nanoparticles and 2)
evaluate the efficacy and toxicity of this selected formulation in comparison with DOXHCl and Doxil®. Formulation 4 was selected for efficacy studies because it displayed the
best in vitro performance, effectively accumulated in tumor tissues and there were not
tumor accumulation differences when compared to Formulation 2. After tolerability and
efficacy testing, it is clear that DOX-SS-NPs (Formulation 4) at a dose of 3 mg/kg is
safer than DOX-HCl administered at the same dose and did not display the cardiac
adverse effects and fatal toxicity observed in mice treated with Doxil®. On the other
hand, there are encouraging results in terms of effective tumor growth inhibition when
administering DOX-SS-NPs. However, a study with a larger sample size will be required
to established, with proper statistical support, the potential differences when comparing
DOX-SS-NPs to DOX-HCl and Doxil®.
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Chapter 7.
Summary and Conclusions
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7.1 Summary
Life-threatening side effects associated to the use of cytotoxic chemotherapeutic
drugs continuous to be a challenge for cancer treatment. Drug encapsulation into
nanoparticles is an alternative to reduce drug concentrations in healthy tissues, and the
subsequent adverse effects, while maintaining or increasing the concentrations that
reach tumor tissues so the anticancer activity is not compromised. Polymeric
nanoparticles from amphiphilic copolymers are deemed as flexible delivery platforms
that efficiently encapsulate hydrophobic drugs and can be tailored to display long term
plasma circulation, effective extravasation across the leaky tumor vasculature and
tissue-specific drug release.
These particular research work involved the formulation and evaluation of
nanoparticles made from amphiphilic copolymers containing cholesterol (hydrophobic
block) and PEG (hydrophilic segment), as delivery vehicles for the anticancer drug
doxorubicin. Initially, we studied the in vivo efficacy and toxicity of DOX encapsulated in
polymeric nanoparticles (DOX-NPs) made from an amphiphilic brush-like block
copolymer composed of polynorbornene-cholesterol/polyethylene glycol (P(NBCh9-bNBPEG)). The formulation development and initial testing of DOX-NPs had been
previously reported by our group but comprehensive in vivo evaluation was lacking.
DOX-NPs proved to be safe for repeated administration. Treatment of tumor-bearing
mice with DOX-NPs significantly reduced tumor growth without inducing free DOX
associated cardiac toxicity, liver toxicity or myelosuppression, providing 100% survival
by the end of the study. The improved safety profile of DOX-NPs derived from low drug
release in plasma as well as reduced drug accumulation in major organs like heart, liver
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and spleen. In this case, a greater dose of DOX-NPs (5 mg/kg DOX equivalents) lead to
similar tumor growth inhibition than 1 mg/kg DOX-HCl (free drug); this need for a higher
dose when administering DOX-NPs could potentially be due to slow drug release from
the nanoparticles. Limited nuclear accumulation of DOX was observed when exposing
cancer cells DOX-NPs, suggesting that slow drug release was preventing the drug from
reaching its intracellular target. Therefore, incorporation of a biologically relevant
cleavable functional group in the polymer structure was proposed as a way to improve
the anticancer activity of these cholesterol based nanoparticles.
A cholesterol-based block copolymer with a reducible disulfide bond (PC5MASS-PEO) was then designed to overcome the slow intracellular drug release issue. We
hypothesized that high tumor glutathione (GSH) concentrations can lead to the
reduction of the disulfide bond in the polymer structure followed by nanoparticle
disruption and subsequent drug release. Initially, we investigated the effect of the
method of preparation and formulation parameters on the characteristics of redoxsensitive nanoparticles containing doxorubicin (DOX-SS-NPs) as an approach to obtain
nanoparticles with optimal particle size distribution, morphology and drug loading for in
vivo administration. A significant influence of the method of preparation and formulation
parameters on the properties of drug-loaded nanoparticles was observed and two
formulations were selected for further in vitro evaluation.
Subsequently, the redox-sensitive nature of nanoparticles prepared with PC5MASS-PEO was confirmed by increased in vitro drug release in biologically relevant
reducing conditions. Significant differences in the rate and extent of in vitro drug
release, cytotoxicity activity in cancer cells and intracellular distribution of DOX were
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observed between the evaluated Formulations (Formulation 2 and Formulation 4),
indicating that the method of preparation can not only affect the properties of drugloaded nanoparticles but also their performance. Remarkably, in this in vitro testing
stage, Formulation 4 proved to be significantly more potent than DOX-NPs (noncleavable nanoparticle) and Doxil®.
Finally, one redox-sensitive formulation was selected based on the in vivo
distribution of the nanoparticles; Formulation 4 was selected for efficacy studies
because it displayed the best in vitro performance, effectively accumulated in tumor
tissues and there were not tumor accumulation differences when compared to
Formulation 2. Subsequently, the in vivo dose tolerability and efficacy of this selected
formulation was evaluated in comparison to DOX-HCl and Doxil®. After tolerability and
efficacy testing, it was clear that DOX-SS-NPs (Formulation 4) at a dose of 3 mg/kg was
safer than DOX-HCl administered at the same dose and did not display the cardiac
adverse effects and fatal toxicity observed in mice treated with Doxil®. Encouraging
results in terms of effective tumor growth inhibition were also observed. However, a
study with a larger sample size is required to established, with proper statistical support,
the potential differences when comparing to DOX-HCl and Doxil®.

7.2 Conclusions and Future Perspective
In this dissertation work, two novel doxorubicin-loaded cholesterol-based NPs
(non-cleavable and cleavable) were formulated and extensively evaluated (in vitro and
in vivo); both types of nanoparticles were efficacious, inhibiting tumor growth in an
animal model, and also displayed better safety profiles than the free form of the drug.
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These findings, support the development of nanomedicines as a valid strategy to
improve the therapeutic index of highly toxic anticancer drugs. In addition, prove of the
advantages associated to bioresponsive (cleavable) carriers was provided in this thesis,
through comprehensive in vitro testing. The experimental outcomes validate the use of
the bioresponsive nanocarrier approach as a way to improve the efficacy of
nanomedicines by facilitating drug release in the dissed tissue and the subsequent
interaction between the drug and its intracellular target.
On the other hand, extensive evidence of the significant influence of the method
of preparation on the characteristics and performance of polymeric NPs was presented
in this thesis, underlying the relevance of formulation optimization when developing this
kind of nanomedicines. The impact of the method of preparation on the properties of
nanomedicines has been previously reported by other research groups. However, the
extent in which the method of preparation can also affect the performance of drugloaded nanoparticles was a knowledge gap addressed by this dissertation. These
results support the adoption of a systematic quality by design approach for the
formulation of this type of non-biological complex drugs, which is currently missing in
academic research.
Remarkably, the encouraging results observed when comparing doxorubicinloaded redox-sensitive nanoparticles (DOX-SS-NPs) vs Doxil® justify conducting future
in vivo efficacy studies with larger sample size in order to establish differences between
these two treatments with appropriate statistical support . Such studies may benefit from
using a tumor model in which glutathione is over-expressed so the redox-sensitive
properties of DOX-SS-NPs can be fully exploit. Additionally, efforts intended to scale up
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the preparation of DOX-SS-NPs are needed in order to conduct the proposed future
efficacy studies.
Finally, in terms of future clinical application, DOX-SS-NPs could be a valuable
therapeutic tool in the context of personalized medicine; patients with tumors displaying
increased reducing status, which can be determined using redox-sensitive imaging
probes, and suffering from cardiac comorbidities could greatly benefit from the
administration of DOX-SS-NPs instead of DOX-HCl or Doxil®, as DOX-SS-NPs
demonstrated increased drug release in reducing conditions and complete absence of
cardiac toxicity.
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